UNITED
      STATES


SECURITIES
      AND EXCHANGE COMMISSION


Washington,
      D.C. 20549





FORM
      10-KSB **/A**


**(Amendment
      No. 1)**




(Mark
      One)


x
            Annual
                Report Pursuant to Section 13 or 15(d) of The Securities Exchange
                Act of
                1934





For
      the
      Fiscal Year Ended December 31, 2007





o
            Transition
                Report Pursuant to Section 13 or 15(d) of The Securities Exchange
                Act of
                1934





Commission
      File Number 000-51140






**CURATECH
                INDUSTRIES,
                INC.**(Name
                of small business issuer in its
                charter)






Nevada
            
            87-0649332(State
                or other jurisdiction of
                incorporation or organization)
            
            (I.R.S.
                EmployerIdentification
                No.)




6337
                Highland Drive, #1053, Salt Lake City, Utah
                84121(Address
                of principal executive offices)
                (Zip Code)




Issuer's
      telephone no.: (801) 616-2355





Securities
      registered pursuant to Section 12(b) of the Exchange Act: None





Securities
      registered pursuant to Section 12(g) of the Exchange Act: Common Stock, $0.001
      par value





Check
      whether the issuer (1) filed all reports required to be filed by Section 13
      or
      15(d) of the Exchange Act during the past 12 months (or for such shorter period
      that the registrant was required to file such reports), and (2) has been subject
      to such filing requirements for the past 90 days. Yes x No o





Check
      if
      there is no disclosure of delinquent filers in response to Item 405 of
      Regulation S-B contained in this form, and no disclosure will be contained,
      to
      the best of the Registrant's knowledge, in definitive proxy or information
      statements incorporated by reference in Part III of this Form 10-KSB or any
      amendment to this Form 10-KSB. o





Indicate
      by check mark whether the registrant is a shell company (as defined in Rule
      12b-2 of the Exchange Act). Yes o
      No x





State
      the
      issuer's revenues for its most recent fiscal year. $ -0-





State
      the
      aggregate market value of the voting stock held by non-affiliates computed
      by reference to the price at which the stock was sold, or the average bid
      and
      ask prices of such stock as of a specified date within 60 days. As of April
      10,
      2008, the aggregate value of the voting stock held by non-affiliates was
      $12,084,603 based upon approximately 8,631,859 shares held by non-affiliates,
      and the average of the bid price ($1.30 per share) and the asked price ($1.50
      per share) of $1.40 per share.





State
      the
      number of shares outstanding of each of the issuer's classes of common equity,
      as of the latest practicable date.




Class
            
            Outstanding
                as of April 14,
                2008Common
                Stock, Par Value
                $0.001
            
            18,555,199
                shares






DOCUMENTS
      INCORPORATED BY REFERENCE





A
      description of "Documents Incorporated by Reference" is contained in Part III,
      Item 13.




Transitional
      Small Business Disclosure Format. Yes o No x





NOTE:
      The
      annual report is being amended for the following purposes:





1.
            To
                correct disclosure under Item 8A Controls and Procedures concerning:
                (i)
                management’s evaluation of its disclosure controls and procedures; and
                (ii) management’s annual report on internal control over financial
                reporting; and


2.
            To
                provide corrected certifications filed as Exhibits 31.1 and 31.2
                which
                inadvertently omitted the portion of the language in the introduction
                to
                the fourth paragraph and in paragraph 4(b) relating to internal control
                over financial reporting.




1




CURATECH
      INDUSTRIES, INC.





TABLE
      OF
      CONTENTS




PagePART
                    IItem
              1
              .
              Description
                  of Business
              3Item
              2
              .
              Description
                  of Property
              12Item
              3
              .
              Legal
                  Proceedings
              12Item
              4
              .
              Submission
                  of Matter to a Vote of Security Holders
              12PART
                  IIItem
              5
              .
              Market
                  for Common Equity and Related Stockholder Matters
              12Item
              6
              .
              Management's
                  Discussion and Analysis or Plan of Operation
              14Item
              7
              .
              Financial
                  Statements
              19Item
              8
              .
              Changes
                  in and Disagreements with Accountants on Accounting andFinancial
                  Disclosure
              32Item
              8
              A.
              Controls
                  and Procedures
              32Item
              8
              B
              Other
                  Information
              32PART
                  IIIItem
              9
              .
              Directors,
                  Executive Officers, Promoters and Control Persons;Compliance
                  with Section 16(a) of the Exchange Act
              33Item
              10
              .
              Executive
                  Compensation
              35Item
              11
              .
              Security
                  Ownership of Certain Beneficial Owners and Managementand
                  Related Stockholder Matters
              37Item
              12
              .
              Certain
                  Relationships and Related Transactions
              38Item
              13
              .
              Exhibits
              39Item
              14
              .
              Principal
                  Accountant Fees and Services
              40Signatures
              41
  2


**PART
      I**








**Item
      1. Description of Business**








Business
      Development





**History**





On
      March
      3, 2000, the board of directors of our former parent corporation, Draco Holding
      Corporation, unanimously approved the formation of Jump'n Jax, Inc., a Utah
      corporation ("Jump'n Jax")(“the Company”), as a wholly-owned subsidiary of the
      Draco. Jump'n Jax operated its business of leasing inflatable balloon
      bounce-houses for parties and outdoor activities in Southern Utah.





From
      its
      formation in March 2000, Jump'n Jax consistently incurred operating losses, with only a few exceptions where it
      showed nominal profits. We financed ongoing operations through various loans
      and
      contributions made by two persons who then served as officers of the Company,
      Messrs. Clissold and Moulton.





On
      January 1, 2006, the board of directors elected to officially cease our bounce
      house operations. This decision was due, in part, to the lack of profitability
      of the operations and the resignation of the primary bounce house operator.
      We
      are deemed to have re-entered the development stage on January 1, 2006.





On
      October 26, 2006, we completed the acquisition of MedaCure International, Inc.,
      a Nevada corporation located in Salt Lake City, Utah (“MedaCure”). The
      acquisition was consummated pursuant to an agreement entered into on June 22,
      2006, whereby we agreed to merge our newly created, wholly-owned subsidiary,
      CuraTech Acquisitions, Inc., with and into MedaCure with MedaCure being the
      surviving entity as our wholly owned subsidiary.





Prior
      to
      completion of the acquisition, on October 4, 2006 we effected a 4 shares for
      1
      share forward stock split of our issued and outstanding shares of common stock
      and changed our corporate name to CuraTech Industries, Inc. As a result of
      the
      forward stock split, our outstanding shares of common stock increased from
      807,602 shares to 3,230,408 shares. We have also changed our corporate domicile
      from the State of Utah to Nevada.





Under
      the
      terms of the merger agreement, we issued an aggregate of approximately
      12,342,239 shares of our common stock, post-split, to the stockholders of
      MedaCure. MedaCure is now a wholly-owned subsidiary of the Company. Also, we
      have added to our board of directors three new directors nominated by
      MedaCure.





**Business
      of MedaCure International, Inc.**





MedaCure
      was organized as a Nevada corporation by Shirlee Dastrup on April 25, 2006
      for
      the purpose of acquiring, developing and marketing a certain health supplement
      that is believed to enhance and build-up the body’s natural immune system
      defenses in both humans and animals. Initially, MedaCure intends to commence
      commercial marketing of its supplement primarily outside the U.S. Initial
      marketing in the U.S. will primarily be to the veterinarian market for use
      in
      treating animals. MedaCure is also looking at the possibility of initiating
      a
      collaboration and partnering program that will focus on developing business
      alliances designed to generate sales, applications and marketing
      opportunities.





MedaCure
      acquired its product pursuant to a purchase agreement in May 2006 from the
      inventor, Dr. William Stacey. Under the terms of the agreement, MedaCure
      acquired all formulas, recipes and manufacturing and marketing rights relating
      to the product in consideration for $150,000 and 537,500 shares of MedaCure
      common stock. Dr. Stacey will serve as a consultant MedaCure’s business and the
      further development and eventual manufacturing and marketing of the product.




3





Presently
      the Company and its subsidiary, MedaCure, maintain their joint office at 6337
      Highland Drive, # 1053, Salt Lake City, Utah 84121, and its telephone number
      is
      (801) 616-2355. Management intends to consider establishing corporate
      headquarters, manufacturing base and laboratory facilities in Orem, Utah,
      located just south of Salt Lake City.





**Product**





The
      MedaCure supplement is manufactured using a variety of components that are
      either natural or previously FDA approved ingredients. The combination of the
      components has not been approved by the FDA. The Company believes that the
      supplement is applicable to both humans and animals and can cause the body’s
      immune system to re-awaken from a state of suppression that can occur due to
      numerous factors including genetic predisposition, types of foods a person
      eats
      and environmental contamination. The Company also believes that the supplement
      can modulate the body’s immune system allowing the system to better fight
      diseases naturally by attacking infections from pathogens (disease producing
      organisms).





The
      immune system is a complex network of specialized organs, glands and cells
      that,
      when working properly, protect the body from pathogens such as virus, bacteria,
      fungus and other foreign tissues. The MedaCure supplement is based on the theory
      that certain chemicals found on the surface of the T 4 lymphocyte (a “helper”
white blood cell) attract pathogens. Activation of the T4 is critical to the
      activation of the immune response. Activation takes place when the T4 cell
      recognizes the antigen displayed by the invading pathogen. An antigen is the
      substance to which the body reacts by producing antibodies. The function of
      the
      T4 is to act as a control for the rest of the immune system. Once activated,
      the
      T4 cell produces immune proteins that in turn activate the “killer” cells. The T
      4 directs and coordinates these other killer cells of the immune system that
      do
      the actual killing of the specific antigen producing pathogen and protects
      the
      body. This is done by chemical signals passed from one cell to another or
      chemical signals released into the blood stream.





Once
      infected by a pathogen, the T4 no longer sends out the proper signals to
      stimulate other cells. The pathogen is attracted to the very spot where the
      T4
      receives messages from other cells. These spots are called "receptors." As
      the
      disease progresses, more and more T4 lymphocytes are infected and can no longer
      receive messages that tell it the body is infected. Slowly the body's ability
      to
      fight off infection declines.





The
      Company believes that the MedaCure product increases the number of cells that
      kill infected cells and increases the number of cells that protect the bodies
      from infection. The supplement is designed to break the attraction the pathogen
      has for the T4 lymphocyte receptor site. Once the T4 is free of the pathogen
      it
      can again send the proper signals to the other cells of the immune system.





MedaCure’s
      supplement can be used by both humans and animals. In humans, it can be taken
      intraveneously (IV), sublingually, orally or by topical cream. IV application
      requires FDA approval, for which MedaCure has not yet applied.




4





**Manufacturing**





The
      Company anticipates that it will require a facility of approximately 5,000
      square feet to manufacture its product. Management anticipates that the facility
      will be leased on a long-term basis. The facility must have a sterile
      environment with an assembly line capable of mass-producing and packaging the
      product. The facility will also handle shipping of product and receiving
      materials. Although the Company has not yet selected the final site for its
      manufacturing facility, it has identified the manufacturing equipment and
      packaging machinery it will need and estimates that the cost to prepare the
      site
      for operation will be approximately $150,000.





**Marketing**





The
      Company plans to sell the MedaCure product to both the health and medical
      industries as well as the veterinarian industry. Initially, MedaCure will
      concentrate on the veterinary market in the U.S. The Company intends to use
      direct selling efforts through pharmaceutical sales personnel, exhibits,
      Internet web site, presentations at trade shows, scientific meetings, medical
      conferences, as well as through networks built up through existing product
      sales
      and distributor relationships. MedaCure is currently beginning to build a
      network of distributors to promote and market its product. The Company also
      intends to establish a collaboration and partnering programs that will focus
      on
      developing business alliances designed to generate sales, applications and
      marketing opportunities.





The
      Company 's initial marketing strategy will focus on establishing distributors
      for a licensing fee. Those territories on which the Company will concentrate
      will include North America (which includes United States and Canada) and Mexico.
      As business warrants and funds are available, the Company intends to expand
      its
      marketing into South America, Europe and other parts of the world.





**Intellectual
      Property and Patent Protection**





MedaCure
      does not presently have any patents related to its product, but intends to
      aggressively defend and expand its intellectual property and technology by
      applying for patent and/or copyright protection in the future as deemed
      necessary. We intend to examine and determine the necessity to secure
      comprehensive intellectual property coverage in the United States and in the
      most relevant foreign markets in anticipation of future commercialization
      opportunities. MedaCure also intends to rely on trade secrets, common law
      trademark rights and trademark registrations, and will continue to protect
      its
      intellectual property via non-disclosure agreements, license agreements and
      limited information distribution.





**Facilities**





The
      Company currently occupies office facilities in Salt Lake City, Utah consisting
      of approximately 500 square feet of office space. Management is presently
      looking for a manufacturing facility, most likely in Orem, Utah, that is located
      approximately 35 miles south of Salt Lake City. Once it locates an appropriate
      laboratory and production facility, the Company will most likely move its
      principal offices to that location. Management believes that it will locate
      and
      secure an acceptable facility in the second quarter of 2007. It is estimated
      that the Company will need a facility of at least 5,000 square feet that is
      capable of housing a sterile manufacturing operation.




5





**Employees**





The
      Company presently has three full time employees and one consultant, but
      anticipates adding employees as it establishes its laboratory and production
      facilities. The Company’s employees are not members of any union, nor have they
      entered into any collective bargaining agreements, nor is it anticipated in
      the
      near future. It is believed that MedaCure’s relationship with its employees is
      good.





**Government
      Regulations**





MedaCure’s
      supplement and its related promotional and marketing activities are subject
      to
      extensive governmental regulation by numerous domestic and foreign governmental
      agencies and authorities, including the FDA, the FTC, the Consumer Product
      Safety Commission, the United States Department of Agriculture, state attorneys
      general and other state regulatory agencies, and similar government agencies
      in
      each country in which we intend to operate. These regulations can limit our
      ability to import products into new markets and can delay introductions of
      new
      products into existing markets as we attempt to comply with the registration
      and
      approval process for our products.





MedaCure’s
      product may be strictly regulated in certain markets in which the Company
      intends to operate. These markets have varied regulations that apply to and
      distinguish nutritional health supplements from “drugs” or “pharmaceutical
      products.” For example, the FDA of the United States under the Federal Food,
      Drug and Cosmetic Act regulates the product. The Federal Food, Drug and Cosmetic
      Act has been amended several times with respect to nutritional supplements,
      most
      recently by the Nutrition Labeling and Education Act and the Dietary Supplement
      Health and Education Act. The Dietary Supplement Health and Education Act
      establishes rules for determining whether a product is a dietary supplement.
      Under this statute, dietary supplements are regulated more like foods than
      drugs, are not subject to the food additive provisions of the law, and are
      generally not required to obtain regulatory approval prior to being introduced
      to the market. None of this limits, however, the FDA’s power to remove an unsafe
      substance from the market. In the event a product, or an ingredient in a
      product, is classified as a drug or pharmaceutical product in any market, we
      would generally not be able to distribute that product in that market through
      our distribution channel because of strict restrictions applicable to drug
      and
      pharmaceutical products.





Most
      existing major markets also regulate product claims and advertising regarding
      the types of claims and representations that can be made regarding the efficacy
      of products, particularly dietary supplements. Accordingly, these regulations
      can limit the Company’s ability to inform consumers of the full benefits of its
      product. For example, in the United States, the Company is unable to make any
      claim that its supplement will diagnose, cure, mitigate, treat or prevent
      disease. The Dietary Supplement Health and Education Act permits only
      substantiated, truthful and non-misleading statements of nutritional support
      to
      be made in labeling, such as statements describing general well-being resulting
      from consumption of a dietary ingredient or the role of a nutrient or dietary
      ingredient in affecting or maintaining a structure or a function of the body.
      In
      addition, all product claims must be substantiated.




6




**Risk
      Factors**





*You
      should carefully consider the risks and uncertainties described below and other
      information in this report. If any of the following risks or uncertainties
      actually occur, our business, financial condition and operating results, would
      likely suffer. Additional risks and uncertainties, including those not yet
      identified or that we currently believe are immaterial, may also adversely
      affect our business, financial condition or operating results.*





**Risks
      Relating to Our Business as a Result of the MedaCure
      Acquisition**





***We
      will require additional financing to proceed with our business activities.
      There
      can be no assurance that financing will be available on terms beneficial to
      us,
      or at all.***





MedaCure
      was recently formed and does not have an operating history. We estimate that
      we
      will need financing of approximately $500,000 during the next 12 months to
      proceed with our anticipated business activities. If we need to raise additional
      capital by selling equity or equity-linked securities, these securities would
      dilute the ownership percentage of our existing stockholders. Also, these
      securities could have rights, preferences or privileges senior to those of
      our
      common stock. If we raise additional capital by issuing debt securities, those
      securities may contain covenants that restrict us in terms of how we operate
      our
      business, which could also affect the value of our common stock. Without
      additional funding, we may not be able to achieve profitable operations, which
      would most likely have a material negative impact on our business and future
      prospects. There can be no assurance that we will be able to raise future
      capital on terms that will be reasonable and beneficial to us, or at
      all.





***MedaCure
      has a limited operating history and has not recorded revenues or operating
      profits since its inception. Continuing losses may exhaust our capital resources
      and force us to discontinue operations.***





MedaCure
      was incorporated in April 2006, has a limited operating history and incurred
      net
      losses since inception. Jump’n Jax, Inc., now known as CuraTech Industries,
      Inc., has been in operation since March 2000, but has realized only nominal
      revenues in recent years and has a net stockholders’ equity of only $47,051 as
      of December 31, 2006. The potential for us to generate future profits depends
      on
      many factors, including the following:





·
            our
                ability to secure adequate funding to complete ongoing research and
                development and to commercially market MedaCure’s
                product;


·
            the
                size and timing of future customer orders, milestone achievement,
                product
                delivery and customer acceptance, if
                required;


·
            success
                in developing, maintaining and enhancing strategic relationships
                with
                potential customers;


·
            our
                ability to protect our intellectual
                property;


·
            actions
                by competitors towards the development and marketing of products
                that will
                compete directly with ours;


·
            the
                costs of maintaining and expanding operations;
                and


·
            our
                ability to attract and retain a qualified work
                force.





There
      can
      be no assurance that we will achieve any of the foregoing factors or realize
      profitability in the immediate future, or at any time.




7





***If
      we cannot achieve commercial application of MedaCure’s product, we may not
      achieve profitability.***





The
      development of a market for MedaCure’s product is dependent on the creation and
      implementation of a successful marketing plan and the acceptance of the product
      in the marketplace. This development may be impacted by many factors including,
      but not limited to the following:





·
            existence
                of competing products and emergence of new
                products;


·
            inability
                to finalize a successful marketing
                strategy;


·
            lack
                of acceptance of MedaCure’s product;
                and


·
            inability
                to adjust to changes in the marketplace and to keep pace with with
                competitors.





If
      we
      fail to develop adequate market for MedaCure’s product or if we are unable to
      successfully compete with other existing and new products, we may not achieve
      profitability.





***Certain
      government regulations concerning approval of MedaCure’s products may negatively
      impact our business following the acquisition of
      MedaCure.***





It
      may be
      necessary for MedaCure’s product to be approved by one or more agencies of the
      Federal government, including the Food and Drug Administration. Government
      regulations concerning the product and its use by humans may be burdensome
      and
      costly and could negatively impact our business. Although we believe the product
      does not require FDA approval for the initial application in the U.S. for animal
      treatment, we do not know the extent to which any such regulations may impact
      the product or our business. Any new regulation may increase costs and could
      reduce our potential to be profitable following completion of the
      merger.





***The
      industry in which MedaCure operates is highly competitive and could affect
      our
      results of operations, which would make profitability even more difficult to
      achieve and sustain.***





The
      health and supplement industry is highly competitive and is marked by rapid
      changes and new products. Other competitors and potential competitors include
      several large national and international companies involved in the health and
      supplement business. Most existing and potential competitors have greater
      financial resources, larger market share, and larger production and technology
      research capability, which may enable them to establish a stronger competitive
      position than we have, in part through greater marketing opportunities. If
      we
      fail to address competitive developments quickly and effectively, we will not
      be
      able to grow our business or remain a viable entity.





***Our
      business could be adversely affected by any adverse economic developments in
      the
      health and supplement industry and/or the economy in general.***





We
      depend
      on the perceived initial demand for the MedaCure product in the U.S. in the
      treatment of animals. Therefore, our business is susceptible to downturns in
      the
      health and supplement industry and the economy in general. Any significant
      downturn in the market or in general economic conditions would likely hurt
      our
      business.




8





***If
      we fail to keep up with changes affecting the MedaCure product and the markets
      that we will ultimately offer the product, we will become less competitive
      and
      thus adversely affect future financial performance.***





In
      order
      to remain competitive and serve its potential effectively, we must respond
      on a
      timely and cost-efficient basis to changes in health and supplement products
      in
      general, industry standards and procedures and customer preferences. Management
      believes that to remain competitive, we will need to continuously develop new
      products and applications for existing products. In some cases these changes
      may
      be significant and the cost to comply with these changes may be substantial.
      We
      cannot assure you that we will be able to adapt to any changes in the future
      or
      that we will have the financial resources to keep up with changes in the
      marketplace. Also, the cost of adapting to changes in MedaCure’s product may
      have a material and adverse effect on our operating results.





***Our
      business could be adversely affected by local, state, national, international
      laws or regulations.***





Our
      future success depends in part on laws and regulations that exist, or are
      expected to be enacted around the world. These laws and regulations could
      negatively affect our business and anticipated revenues. We cannot guarantee
      a
      positive outcome in direction, timing, or scope of laws and regulations that
      may
      be enacted which will affect our business.





***Our
      future success depends on retaining our existing key employees and hiring and
      assimilating new key employees. The loss of key employees or the inability
      to
      attract new key employees could limit our ability to execute our growth
      strategy, resulting in lost sales and a slower rate of
      growth.***





Our
      future success depends in part on our ability to retain our key employees
      including its executive officers. Although following the acquisition we expect
      to have employment agreements with these executives, each executive may be
      able
      to terminate his or her agreement at any time. We anticipate obtaining in the
      futures "key man" insurance for one or more of our key executives. It would
      be
      difficult for us to replace any one of these individuals. In addition, as we
      grow we may need to hire additional key personnel. We may not be able to
      identify and attract high quality employees or successfully assimilate new
      employees into our existing management structure.





***We
      may be unable to protect our intellectual property adequately or cost
      effectively, which may cause us to lose market share or reduce
      prices.***





Our
      future success depends in part on our ability to protect and preserve
      proprietary rights related to MedaCure’s product. We cannot assure you that we
      will be able to prevent third parties from using our intellectual property
      rights and technology without our authorization. Although we have not obtained
      any patents on its product, it may in the future file for patent protection
      for
      its product and will also rely on trade secrets, common law trademark rights
      and
      trademark registrations. We will also employ confidentiality and work for hire,
      development, assignment and license agreements with employees, consultants,
      third party developers, licensees and customers. However, these measures afford
      only limited protection and may be flawed or inadequate. Also, enforcing
      intellectual property rights could be costly and time-consuming and could
      distract management’s attention from operating business matters.





***Our
      intellectual property may infringe on the rights of others, resulting in costly
      litigation.***





In
      recent
      years, there has been significant litigation in the United States involving
      patents and other intellectual property rights. In particular, there has been
      an
      increase in the filing of suits alleging infringement of intellectual property
      rights, which pressure defendants into entering settlement arrangements quickly
      to dispose of such suits, regardless of their merits. Other companies or
      individuals may allege that we infringe on their intellectual property rights.
      Litigation, particularly in the area of intellectual property rights, is costly
      and the outcome is inherently uncertain. In the event of an adverse result
      against future rights we may acquire, we could be liable for substantial damages
      and we may be forced to discontinue our use of the subject matter in question
      or
      obtain a license to use those rights or develop non-infringing alternatives.
      Any
      of these results would increase our cash expenditures, adversely affecting
      our
      financial condition.




9





***We
      may not be able to manage future growth effectively, which could adversely
      affect our operations and financial performance.***





The
      ability to manage and operate our business as we execute our development and
      growth strategy will require effective planning. Possible future growth could
      strain our management and internal resources and cause other problems that
      could
      adversely affect our financial performance. We expect that our efforts to grow
      will place a significant strain on personnel, management systems, infrastructure
      and other resources. Our ability to manage future growth effectively will also
      require us to successfully attract, train, motivate, retain and manage new
      employees and continue to update and improve our operational, financial and
      management controls and procedures. If we do not manage our growth effectively,
      our operations could be adversely affected, resulting in slower growth and
      a
      failure to achieve or sustain profitability.





***Being
      a public company involves increased administrative costs, which could result
      in
      lower net income and make it more difficult for us to attract and retain key
      personnel.***





As
      a
      public company, we incur significant legal, accounting and other expenses that
      MedaCure did not incur as a private company. In addition, the Sarbanes-Oxley
      Act
      of 2002 as well as new rules subsequently implemented by the SEC, have required
      changes in corporate governance practices of public companies. We expect that
      these new rules and regulations will increase our legal and financial compliance
      costs and make some activities more time consuming. For example, in connection
      with being a public company, we may have to create several board committees,
      implement additional internal controls and disclose controls and procedures,
      retain a transfer agent and financial printer, adopt an insider trading policy
      and incur costs relating to preparing and distributing periodic public reports
      in compliance with our obligations under securities laws. These new rules and
      regulations could also make it more difficult for us to attract and retain
      qualified executive officers and members of our board of directors, particularly
      to serve on our audit committee.





**Risks
      Relating to Ownership of Our Common Stock**





***We
      cannot assure you that there will be an active trading market for our common
      stock and it could be difficult for holders of our common stock to liquidate
      their shares.***





Even
      though we expect our common stock to continue to be quoted on the OTC Bulletin
      Board, we cannot predict the extent to which a trading market will develop
      or
      how liquid that market might become. Also, most shares outstanding after the
      acquisition of MedaCure, including those issued pursuant to the acquisition,
      are
      deemed "restricted securities" within the meaning of Rule 144 promulgated by
      the
      SEC and will therefore be subject to certain limitations on the ability of
      holders to resell such shares. Because only a small percentage of our
      outstanding shares are freely tradeable in the public market, the price of
      our
      shares could be volatile and liquidation of a person’s holdings may be
      difficult. Thus, holders of our common stock may be required to retain their
      shares for a long period of time.




10





***We
      do not anticipate paying dividends in the foreseeable future, which could make
      our stock less attractive to potential investors.***





We
      anticipate that we will retain any future earnings and other cash resources
      for
      future operation and development of our business and do not intend to declare
      or
      pay any cash dividends in the foreseeable future. Any future payment of cash
      dividends will be at the discretion of our board of directors after taking
      into
      account many factors, including our operating results, financial condition
      and
      capital requirements. Corporations that pay dividends may be viewed as a better
      investment than corporations that do not.





***Future
      sales or the potential for sale of a substantial number of shares of our common
      stock could cause our market value to decline and could impair our ability
      to
      raise capital through subsequent equity offerings.***





Sales
      of
      a substantial number of shares of our common stock in the public markets, or
      the
      perception that these sales may occur, could cause the market price of our
      common stock to decline and could materially impair our ability to raise capital
      through the sale of additional equity securities. In addition to the
      approximately 15,572,647 common shares issued and outstanding at the completion
      of the MedaCure acquisition, there will be approximately another 37 million
      shares of authorized, but unissued common stock that may be issued in the
      future.





***It
      may be difficult for a third party to acquire us, and this could depress our
      stock price.***





Under
      Nevada corporate law, we are permitted to include or exclude certain provisions
      in our articles of incorporation and/or by-laws that could discourage
      information contests and make it more difficult for you and other stockholders
      to elect directors and take other corporate actions. As a result, these
      provisions could limit the price that investors are willing to pay in the future
      for shares of our common stock. For example:





·
            Without
                prior stockholder approval, the board of directors has the authority
                to
                issue one or more classes of preferred stock with


rights
      senior to those of common stock and to determine the rights, privileges and
      inference of that preferred stock;


·
            Under
                Nevada law, we are not required to provide for, and our


by-laws
      do not provide for, cumulative voting in the election of directors, which would
      otherwise allow less than a majority of stockholders to elect director
      candidates; and


·
            Stockholders
                cannot call a special meeting of
                stockholders.





***Trading
      in our shares may be subject to certain "penny stock” regulation which could
      have a negative effect on the price of our shares in the public trading
      market.***





Public
      trading of our common stock on the OTCBB may be subject to certain provisions,
      commonly referred to as the penny stock rule, promulgated under the Securities
      Exchange Act of 1934. A penny stock is generally defined to be any equity
      security that has a market price less than $5.00 per share, subject to certain
      exceptions. If our stock is deemed to be a penny stock, trading in our stock
      will be subject to additional sales practice requirements on broker-dealers.
      These may require a broker dealer to:





·
            make
                a special suitability determination for purchasers of penny
                stocks;


·
            receive
                the purchaser's written consent to the transaction prior to the purchase;
                and


·
            deliver
                to a prospective purchaser of a penny stock, prior to the first
                transaction, a risk disclosure document relating to the penny stock
                market.




11




Consequently,
      penny stock rules may restrict the ability of broker-dealers to trade and/or
      maintain a market in our common stock. Also, many prospective investors may
      not
      want to get involved with the additional administrative requirements, which
      may
      have a material adverse effect on the trading of our shares.





**Item
      2. Description of Property**








We
      do not
      presently own any property. We currently occupy office facilities in Salt Lake
      City, Utah consisting of approximately 500 square feet of office space.
      Management is presently looking for a manufacturing facility, most likely in
      Orem, Utah, that is located approximately 35 miles south of Salt Lake City.
      Once
      we locate an appropriate laboratory and production facility, we will most likely
      move our principal offices to that location. Management believes that we will
      locate and secure an acceptable facility in the second or third quarter of
      2008.
      It is estimated that we will need a facility of at least 5,000 square feet
      that
      is capable of housing a sterile manufacturing operation.








**Item
      3. Legal Proceedings**








There
      are
      no material pending legal proceedings to which we or our subsidiary is a party
      or to which any of our property is subject and, to the best of our knowledge,
      no
      such action against us is contemplated or threatened.







**Item
      4. Submission of Matters to a Vote of Security Holders**








No
      matter
      was submitted to a vote of our security holders, through the solicitation of
      proxies or otherwise, during the fourth quarter of the fiscal year covered
      by
      this report.




**PART
      II**







**Item
      5. Market for Common Equity and Related Stockholder
      Matters**








**Market
      Information**





Our
      common stock is currently included on the OTC Bulletin Board under the symbol
      “CUTC.OB” (previously “JMPJ”). The shares are thinly traded and a limited market
      presently exists for the shares. The following table describes, for the
      respective periods indicated, the prices of the Company common stock in the
      over-the-counter market, based on inter-dealer bid prices, without retail
      mark-up, mark-down or commissions and may not necessarily represent actual
      transactions. The quotations have been provided by market makers in common
      stock
      and/or Pink Sheets LLC.




12




Quarter
                  ended
              
              High
                  bid
              
              Low
                  bidMarch
                  31, 2006
              
              $
              2.00
              
              $
              1.15June
                  30,2006
              
              $
              5.25
              
              $
              1.50September30,2006
              
              $
              10.10
              
              $
              4.50December31,2006
              
              $
              5.55
              
              $
              1.35March
                  31,2007
              
              $
              2.00
              
              $
              1.65June
                  30,2007
              
              $
              2.00
              
              $
              1.50September30,2007
              
              $
              3.00
              
              $
              1.70December31,2007
              
              $
              2.35
              
              $
              0.51


The
      prices listed in the table above have been adjusted to effect the 4 for 1
      forward stock split of the Company’s shares that occurred on October 4,
      2006.





**Stockholders**





Presently
      we have approximately 217 holders of record of our common stock. T his
      number does not take into consideration stockholders whose shares are held by
      broker-dealers, financial institutions or other nominees.





**Dividend
      Policy**





We
      have
      never declared or paid cash dividends or made distributions in the past
      and
      do not anticipate paying cash dividends or making distributions in the foreseeable
      future. We currently intend to retain and invest future earnings to finance
      operations. There are no material restrictions limiting, or that are likely
      to
      limit, The Company’s ability to pay dividends on our securities, except for any
      applicable limitations under Nevada corporate law.





**Recent
      sales of unregistered securities**





During
      the past three years ended December 31, 2007, The Company has not sold any
      shares of its common stock without registration under the Securities Act of
      1933, except for the following:





(1)  On
      May
      20, 2005, the board of directors authorized the issuance of a total of 1,333,336
      post-split shares of common stock, separately, to Lane S. Clissold (666,668)
      and
      Steven D. Moulton (666,668), two of the Company’s former officers. The shares
      were issued in consideration for Messrs. Clissold's and Moulton's agreement
      to
      convert into shares of common stock all amounts due and owing to them resulting
      from loans and/or advances made to the Company. As a result of the issuance,
      the
      loans and/or advances made by Messrs. Clissold and Moulton to the Company
      through May 15, 2005, and all accrued interest thereon, were deemed to be paid
      in full. The shares were valued at $0.1935 per share for total consideration
      of
      $64,500.





(2)  On
      May
      25, 2005, the Company authorized the issuance of 133,332 post-split shares
      of
      common stock to an unrelated individual pursuant to a service agreement as
      consideration for services rendered to the Company. The shares valued at $0.03
      per share for total consideration of $4,000.





(3)  In
      May
      2006, the Company issued 800,000 common shares to an unrelated third party
      in
      exchange for services rendered and $30,000 in cash.





(4)  In
      October 2006 the Company issued an aggregate of 12,342,239 shares of common
      stock to approximately 54 persons as consideration for the acquisition of
      MedaCure International, Inc.





(5)  During
      the first quarter of 2007, the Company issued 317,552 shares of its common
      stock
      for cash and subscriptions receivable at $1.50 per share.




13





(6)  During
      the second quarter of 2007, the Company issued 890,000 shares of common stock
      for services at $1.50 per share.





(7)  During
      the fourth quarter of 2007, the Company issued 800,000 shares of its common
      stock to a non-affiliate for services rendered at a value of $1.01 per share,
      and the Company issued 1,000,000 shares of its common stock to The Dastrup
      Family Trust at a value of $1.01 per share. Lincoln Dastrup and Linda L. Dastrup
      are trustees of The Dastrup Family Trust which is an irrevocable family trust.
      Mr. and Mrs. Dastrup and their five children are beneficiaries of The Dastrup
      Family trust.





In
      each
      transaction, the shares were issued without registration pursuant to Section
      4(2) of the Securities Act of 1933 and/or Rule 506 of Regulation D for a
      transaction not involving any public offering. The certificates representing
      the
      shares were given a restricted legend.








**Item
      6. Management's Discussion and Analysis or Plan of
      Operation**





The
      following information should be read in conjunction with the financial
      statements and notes thereto appearing elsewhere in this Form
      10-KSB.





**Plan
      of Operation**





Following
      the formation of the Company in March 2000, the Company operated its business
      of
      inflatable balloon bounce-houses for parties and outdoor activities in Southern
      Utah until approximately January 2006, when the Board of directors elected
      to
      cease bounce house operations due, in part, to the lack of profitability and
      the
      resignation of the primary bounce house operator.





Following
      the completion of the acquisition of MedaCure on October 26, 2006, we have
      become engaged in the developing and marketing of MedaCure’s health supplement
      that is believed to enhance and build-up the body’s natural immune system
      defenses in both humans and animals. Our first priority will be to establish
      new
      facilities for our corporate headquarters and to manufacture product. Management
      is seeking at least a 5,000 square foot facility that can be leased on a
      long-term basis. The facility must have a sterile environment with an assembly
      line capable of mass-producing and packaging the product. The facility will
      also
      handle shipping of product and receiving materials. We have not selected a
      final
      site, but we have identified the necessary manufacturing equipment and packaging
      machinery needed. We estimate that the cost to prepare the site for operation
      will be approximately $150,000.





Contemporaneous
      with selecting the site for our operations, we will be creating a distribution
      network that will focus on initiating a collaboration and partnering program
      and
      developing business alliances designed to generate sales, applications and
      marketing opportunities. At present, we have not hired any sales or distribution
      personnel, but are in the process of initiating a search for qualified persons.
      We anticipate that during the next 12 months we will hire approximately 20
      persons, five for administrative duties, six for manufacturing and production,
      and nine for sales and marketing.





We
      estimate that during the next 12 months we will need approximately $600,000
      to
      establish our manufacturing facility, establish a sales and distribution
      network, commence production of the MedaCure product and begin selling
      activities. We anticipate that the source of these funds will be from the
      private sale of securities and/or other financing activities conducted by our
      officers and directors. We anticipate that we will be able to raise
      approximately $2,800,000 during 2008.




14





**Inflation**





In
      the
      opinion of management, inflation has not and will not have a material effect
      on
      our operations in the immediate future. Management will continue to monitor
      inflation and evaluate the possible future effects of inflation on our business
      and operations.





**Results
      of Operations**





For
      the
      Period from Inception on April 25, 2006 through December 31, 2007.





Revenues
      from continuing operations for the years ended December 31, 2007 and 2006 were
      both $-0-. This lack of revenues was due primarily to the fact that our business
      pertaining to the Medacure subsidiary has not yet been sufficiently
      developed.





Total
      operating expenses for the period ending December 31, 2007 were $3,536,669
      which
      consisted of $3,535,307 of general and administrative expenses and $1,362 in
      depreciation. General and administrative expenses increased $3,044,867 from
      the
      $108,133 of general and administrative expenses incurred during the period
      from
      inception of the development stage on April 25, 2006 through December 31, 2006.
      The increase in general and administrative expenses is largely due to a charge
      of $3,153,000 for the issuance of 2,690,000 shares of the Company’s common stock
      for services rendered. We reported a net loss of $3,532,789, or $0.22 per share,
      for the period ended December 31, 2007, an increase of $2,952,156 over the
      net
      loss of $580,633, or $0.07 per share, reported for the period from inception
      of
      the development stage on April 25, 2006 through December 31, 2006. The increase
      in net loss for the year ended December 31, 2007 was largely a result of a
      substantial increase in general and administrative expenses associated with
      the
      issuance of shares of the Company’s common stock for services, partially offset
      by a $472,500 reduction in impairment of assets.





**Liquidity
      and Capital Resources**





At
      December 31, 2007, we had cash on hand of $58,160 and a note receivable-related
      party of $74,005. We believe that current cash on hand is not sufficient to
      satisfy our cash requirements for the next twelve months, which we estimate
      to
      be approximately $600,000. Due to the fact that our limited operations have
      not
      generated cash flow sufficient to cover ongoing business expenses and/or we
      purchase additional equipment, we may have to rely on our directors, or on
      outside sources, to provide additional funds. However, we have no agreements
      with anyone to provide future funds to our Company. If our directors are unable
      to provide future funding, if the need arises, we may have to look at
      alternative sources of funding. Presently we are attempting to raise funds
      through a private placement of our shares of common stock. We do not have any
      firm commitments from third parties to provide funding, and there is no
      assurance that such funds will be available or, that even if they are available,
      that they will be available on terms that will be acceptable to us. In the
      event
      we are unable to secure necessary future funding, we may have to curtail our
      business or cease operations completely.





As
      reported by the Company’s auditors in Note 5 of our audited financial
      statements, the Company has not established revenues sufficient to cover its
      operating costs and allow it to continue as a going concern.





At
      December 31, 2007, we had total assets of $141,494 and stockholders' equity
      of
      $141,119.





**Net
      Operating Loss**





We
      have
      accumulated approximately $190,000 of net operating loss carryforwards as of
      December 31, 2007, which may be offset against taxable income and income taxes
      in future years. The use of these losses to reduce future income taxes will
      depend on the generation of sufficient taxable income prior to the expiration
      of
      the net operating loss carryforwards. The carry-forwards expire in the year
      2027. In the event of certain changes in control, there will be an annual
      limitation on the amount of net operating loss carryforwards which can be used.
      No tax benefit has been reported in the financial statements for the year ended
      December 31, 2007 because there is a 50% or greater chance that the carryforward
      will not be used. Accordingly, the potential tax benefit of the loss
      carryforward is offset by a valuation allowance of the same amount.




15





**Forward
      Looking and Cautionary Statements**





This
      report, including the sections entitled "Business," "Risk Factors" and
      "Management's Discussion and Analysis or Plan of Operations" contains
      forward-looking statements. These statements relate to future events or our
      future financial performance and involve known and unknown risks and
      uncertainties. These factors may cause our company's or our industry's actual
      results, levels of activity, performance or achievements to be materially
      different from those expressed or implied by the forward- looking statements.
      These risks and other factors include those listed under "Risk Factors" and
      elsewhere in this report. In some cases, you can identify forward-looking
      statements by terminology such as "may," "will" "should," "expects," "intends,"
      "plans," anticipates," "believes," "estimates," "predicts," "potential,"
      "continue," or the negative of these terms or other comparable
      terminology.





You
      should be aware that a variety of factors could cause actual results to differ
      materially from the anticipated results or other matters expressed in
      forward-looking statements. These risks and uncertainties, many of which are
      beyond our control, include:





*
            the
                sufficiency of existing capital resources and our ability to raise
                additional capital to fund cash requirements for future
                operations;





*
            uncertainties
                following any successful acquisition or merger related to the future
                rate
                of growth of our business and acceptance of our products and/or services;





*
                volatility
                    of the stock market, particularly within the technology sector;
                    and





*
                general
                    economic conditions.





Although
      we believe the expectations reflected in these forward-looking statements are
      reasonable, such expectations cannot guarantee future results, levels of
      activity, performance or achievements.





You
      are
      cautioned that any forward-looking statements are not guarantees of future
      performance and are subject to risks and uncertainties. Actual results may
      differ materially from those included within the forward-looking statements
      as a
      result of various factors. Cautionary statements in the risk factors section
      and
      elsewhere in this report identify important risks and uncertainties affecting
      our future, which could cause actual results to differ materially from the
      forward-looking statements made in this report.





**Recent
      Accounting Pronouncements**





SFAS
      No. 157, *Fair
      Value Measurements* **-** This
      Statement does not require any new fair value measurements, but rather, it
      provides enhanced guidance to other pronouncements that require or permit assets
      or liabilities to be measured at fair value. However, the application of this
      Statement may change how fair value is determined. The Statement is effective
      for financial statements issued for fiscal years beginning after November 15,
      2007, and interim periods within those fiscal years. As of December 1, 2007
      the
      FASB has proposed a one-year deferral for the implementation of the Statement
      for nonfinancial assets and nonfinancial liabilities that are recognized or
      disclosed at fair value in the financial statements on a nonrecurring basis.
      The
      implementation of this pronouncement had no material effect on the Company’s
      financial statements.




16





SFAS
      No. 158, *Employers’
      Accounting for Defined Benefit Pension and Other Postretirement Plans - an
      amendment of FASB Statements No. 87, 88, 106, and 132(R)* *-* This
      Statement requires that employers measure plan assets and obligations as of
      the
      balance sheet date. This requirement is effective for fiscal years ending after
      December 15, 2008. The other provisions of the Statement were effective as
      of
      the end of the fiscal year ending after December 15, 2006, for public companies.
      The implementation of this pronouncement had no material effect on the Company’s
      financial statements.





SFAS
      No. 159, *The
      Fair Value Option for Financial Assets and Financial Liabilities - Including
      an
      amendment of FASB Statement No. 115* *-* This
      Statement provides all entities with an option to report selected financial
      assets and liabilities at fair value. The Statement is effective as of the
      beginning of an entity’s first fiscal year beginning after November 15, 2007,
      with early adoption available in certain circumstances. The implementation
      of
      this pronouncement had no material effect on the Company’s financial
      statements.





SOP
      No. 07-01, *Clarification
      of the Scope of the Audit and Accounting Guide “Investment Companies” and
      Accounting by Parent Companies and Equity Method Investors for Investments
      in
      Investment Companies* *-* SOP
      07-01 provides guidance for determining whether an entity is within the scope
      of
      the AICPA Audit and Accounting Guide *Investment
      Companies.* The
      provisions of the SOP are effective for fiscal years beginning on or after
      December 15, 2007, with earlier application encouraged. As of December 1, 2007
      the FASB has proposed an indefinite deferral of this SOP. The implementation
      of
      this pronouncement had no effect on the Company’s financial
      statements.





*EITF
      Issue No. 06-1, Accounting for Consideration Given by a Service Provider to
      a
      Manufacturer or Reseller of Equipment Necessary for an End-Customer to Receive
      Service from the Service Provider* **-** This
      consensus concludes that if the consideration given by a service provider to
      a
      manufacturer or reseller (that is not a customer of the service provider) can
      be
      linked contractually to the benefit received by the service provider's customer,
      the service provider should account for the consideration in accordance with
      EITF Issue 01-9. The consensus is effective for the first annual reporting
      period beginning after June 15, 2007. The implementation of this pronouncement
      had no effect on the Company’s financial statements.





*EITF
      Issue No. 06-4, Accounting for Deferred Compensation and Postretirement Benefit
      Aspects of Endorsement Split-Dollar Life Insurance
      Arrangements* **-** This
      consensus concludes that for a split-dollar life insurance arrangement within
      the scope of this Issue, an employer should recognize a liability for future
      benefits in accordance with FASB Statement No. 106 (if, in substance, a
      postretirement benefit plan exists) or APB Opinion No. 12 (if the arrangement
      is, in substance, an individual deferred compensation contract) based on the
      substantive agreement with the employee. The consensus is effective for fiscal
      years beginning after December 15, 2007, with early application permitted.
      The
      implementation of this pronouncement had no effect on the Company’s financial
      statements.





*EITF
      Issue No. 06-8, Applicability of the Assessment of a Buyer's Continuing
      Investment under FASB Statement No. 66, “Accounting for Sales of Real Estate”,
      for Sales of Condominiums* **-** This
      consensus concludes that an entity is required to evaluate the adequacy of
      a
      buyer’s initial and continuing investment for purposes of determining whether it
      is appropriate to recognize profit from a real estate sale involving a
      condominium unit or time-sharing interest under the percentage-of-completion
      method under Statement No. 66. The consensus is effective for the first annual
      reporting period beginning after March 15, 2007. The implementation of this
      pronouncement had no effect on the Company’s financial statements.




17





*EITF
      Issue No. 06-10, Accounting for Collateral Assignment Split-Dollar Life
      Insurance Arrangements* **-** In
      this
      Issue, a consensus was reached that an employer should recognize a liability
      for
      the postretirement benefit related to a collateral assignment split-dollar
      life
      insurance arrangement in accordance with either FASB Statement No. 106 or APB
      Opinion No. 12, as appropriate, if the employer has agreed to maintain a life
      insurance policy during the employee's retirement or provide the employee with
      a
      death benefit based on the substantive agreement with the employee. A consensus
      also was reached that an employer should recognize and measure an asset based
      on
      the nature and substance of the collateral assignment split-dollar life
      insurance arrangement. The consensuses are effective for fiscal years beginning
      after December 15, 2007, including interim periods within those fiscal years,
      with early application permitted. The implementation of this pronouncement
      had
      no effect on the Company’s financial statements.





*EITF
      Issue No. 06-11, Accounting for Income Tax Benefits of Dividends on Share-Based
      Payment Awards* **-** In
      this
      Issue, a consensus was reached that a realized income tax benefit from dividends
      or dividend equivalents that are charged to retained earnings and are paid
      to
      employees for equity-classified nonvested equity shares, nonvested equity share
      units, and outstanding equity share options should be recognized as an increase
      in additional paid-in capital. This Issue should be applied prospectively to
      the
      income tax benefits that result from dividends on equity-classified employee
      share-based payment awards that are declared in fiscal years beginning after
      December 15, 2007, and interim periods within those fiscal years. Early
      application is permitted. The implementation of this pronouncement had no effect
      on the Company’s financial statements.





*EITF
      Issue No. 07-3, Accounting for Nonrefundable Advance Payments for Goods or
      Services Received for Use in Future Research and Development
      Activities* **-** In
      this
      Issue, a consensus was reached that *nonrefundable* advance
      payments for future research and development activities should be deferred
      and
      capitalized. This Issue is effective for financial statements issued for fiscal
      years beginning after December 15, 2007, and interim periods within those fiscal
      years. Early application is not permitted. The implementation of this
      pronouncement had no effect on the Company’s financial statements.





*FSP
      No. FAS 158-1, Conforming Amendments to the Illustrations in FASB Statements
      No.
      87, No. 88, and No. 106 and to the Related Staff Implementation
      Guides* **-** This
      FSP
      provides conforming amendments to the illustrations in FASB Statements No.
      87,
      88, and 106 and to related staff implementation guides as a result of the
      issuance of FASB Statement No. 158. The conforming amendments made by this
      FSP
      are effective as of the effective dates of Statement No. 158. The unaffected
      guidance that this FSP codifies into Statements No. 87, 88, and 106 does not
      contain new requirements and therefore does not require a separate effective
      date or transition method. The implementation of this pronouncement had no
      effect on the Company’s financial statements.





*FSP
      No. FIN 39-1, Amendment of FASB Interpretation No. 39* *-* This
      FSP
      amends FASB Interpretation (FIN) No. 39, *Offsetting
      of Amounts Related to Certain Contracts,* to
      permit
      a reporting entity to offset fair value amounts recognized for the right to
      reclaim cash collateral or the obligation to return cash collateral against
      fair
      value amounts recognized for derivative instruments executed with the same
      counterparty under the same master netting arrangement that have been offset
      in
      accordance with paragraph 10 of FIN 39. The guidance in this FSP is effective
      for fiscal years beginning after November 15, 2007, with early application
      permitted. The implementation of this pronouncement had no effect on the
      Company’s financial statements.




18





*FSP
      No. FIN 46(R)-7, Application of FASB Interpretation No. 46(R) to Investment
      Companies* **-** This
      FSP
      addresses the application of FASB Interpretation (FIN) No. 46 (revised December
      2003), *Consolidation
      of Variable Interest Entities* ,
      by an
      entity that accounts for its investments in accordance with the specialized
      accounting guidance in the AICPA Audit and Accounting Guide, *Investment
      Companies* .
      The
      provisions of the FSP are effective when the entity adopts SOP 07-01. The
      implementation of this pronouncement had no effect on the Company’s financial
      statements.





*SEC
      Staff Accounting Bulletin No. 109, Written Loan Commitments Recorded at Fair
      Value Through Earnings* ***-*** SAB
      109
      expresses the current view of the staff that the expected net future cash flows
      related to the associated servicing of the loan should be included in the
      measurement of all written loan commitments that are accounted for at fair
      value
      through earnings.  SEC registrants are expected to apply the views in
      Question 1 of SAB 109 on a prospective basis to derivative loan commitments
      issued or modified in fiscal quarters beginning after December 15, 2007. The
      implementation of this pronouncement had no effect on the Company’s financial
      statements.







**Item
      7. Financial Statements**





Financial
      statements for the fiscal years ended December 31, 2007 and 2006 have been
      examined to the extent indicated in their reports by Moore & Associates,
      Chartered, independent certified public accountants and have been prepared
      in
      accordance with generally accepted accounting principles and pursuant to
      Regulation S-B as promulgated by the SEC. The aforementioned financial
      statements are included below.







**CURATECH
      INDUSTRIES, INC.**





**FINANCIAL
      STATEMENTS**





December
      31, 2007




19








**MOORE
      & ASSOCIATES, CHARTERED**


** *ACCOUNTANTS
      AND ADVISORS*


*PCAOB
      REGISTERED*





REPORT
      OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM








To
      the
      Board of Directors


CuraTech
      Industries, Inc.


(A
      Development Stage Company)





We
      have
      audited the accompanying balance sheet of CuraTech Industries, Inc. (a
      development stage company) as of December 31, 2007, and the related statements
      of operations, stockholders’ equity and cash flows for the year ended December
      31, 2007, since inception on April 25, 2006 through December 31, 2006, and
      since
      inception on April 25, 2006 through December 31, 2007. These financial
      statements are the responsibility of the Company’s management. Our
      responsibility is to express an opinion on these financial statements based
      on
      our audits.





We
      conducted our audits in accordance with standards of the Public Company
      Accounting Oversight Board (United States). Those standards require that we
      plan
      and perform the audits to obtain reasonable assurance about whether the
      financial statements are free of material misstatement. An audit includes
      examining, on a test basis, evidence supporting the amounts and disclosures
      in
      the financial statements. An audit also includes assessing the accounting
      principles used and significant estimates made by management, as well as
      evaluating the overall financial statement presentation. We believe that our
      audits provide a reasonable basis for our opinion.





In
      our
      opinion, the financial statements referred to above present fairly, in all
      material respects, the financial position of CuraTech Industries, Inc. (a
      development stage company) **** as
      of
      December 31, 2007, and the related statements of operations, stockholders’
equity and cash flows for the year ended December 31, 2007, since inception
      on
      April 25, 2006 through December 31, 2006, and since inception on April 25,
      2006
      through December 31, 2007 in conformity with accounting principles generally
      accepted in the United States of America.





The
      accompanying financial statements have been prepared assuming that the Company
      will continue as a going concern. As discussed in Note 2 to the financial
      statements, the Company has not established revenues sufficient to cover its
      operating costs, which raises substantial doubt about its ability to continue
      as
      a going concern. Management’s plans concerning these matters are also described
      in Note 2. The financial statements do not include any adjustments that might
      result from the outcome of this uncertainty.





*/s/
      Moore & Associates Chartered*





Moore
      & Associates Chartered


Las
      Vegas, Nevada


April
      3,
      2008











*2675
      S. Jones Blvd. Suite 109, Las Vegas, NV 89146 (702) 253-7511 Fax (702)
      253-7501*




20




**CURATECH
                    INDUSTRIES, INC.**(A
                    Development Stage Company)Balance
                    Sheet
 
 ASSETSDecember
                      31,2007CURRENT
                    ASSETSCash
                
                $
                58,160Note
                    receivable - related party
                
                
                74,005Interest
                    receivable - related party
                
                
                3,880Total
                    Current Assets
                
                
                136,045FIXED
                    ASSETS, Net
                
                
                5,449TOTAL
                    ASSETS
                
                $
                141,494LIABILITIES
                    AND STOCKHOLDERS' EQUITY (DEFICIT)CURRENT
                    LIABILITIESAccounts
                    payable
                
                $
                375Total
                    Current Liabilities
                
                
                375TOTAL
                    LIABILITIES
                
                
                375STOCKHOLDERS'
                    EQUITY (DEFICIT)Common
                    stock: 25,000,000 shares authorized;$0.001
                    par value; 18,580,199 shares issued andoutstanding
                
                
                18,580Additional
                    paid-in capital
                
                
                4,335,213Stock
                    subscriptions receivable
                
                
                (99,252
                )Deficit
                    accumulated during the development stage
                
                
                (4,113,422
                )Total
                    Stockholders' Equity (Deficit)
                
                
                141,119TOTAL
                    LIABILITIES AND STOCKHOLDERS'EQUITY
                    (DEFICIT)
                
                $
                141,494
  The
                    accompanying notes are an integral part of these financial
                    statements.
  21
  **CURATECH
                    INDUSTRIES, INC.**(A
                    Development Stage Company)Statements
                    of Operations
 
 For
                          theYear
                          EndedDecember
                          31,2007
                
                From
                                Inceptionof
                                theDevelopmentStage
                                onApril
                                25, 2006throughDecember
                                31,2006
                
                From
                                Inceptionof
                                theDevelopmentStage
                                onApril
                                25 2006,throughDecember
                                31,2007REVENUES
                
                $
                -
                
                $
                -
                
                $
                -OPERATING
                    EXPENSESGeneral
                    and administrative
                
                
                3,535,307
                
                
                108,133
                
                
                3,643,440Depreciation
                
                
                1,362
                
                
                -
                
                
                1,362Total
                    Operating Expenses
                
                
                3,536,669
                
                
                108,133
                
                
                3,644,802LOSS
                    FROM OPERATIONS
                
                
                (3,536,669
                )
                
                (108,133
                )
                
                (3,644,802
                )OTHER
                    EXPENSESImpairment
                    of assets
                
                
                -
                
                
                (472,500
                )
                
                (472,500
                )Interest
                    income
                
                
                3,880
                
                
                -
                
                
                3,880Total
                    Other Expenses
                
                
                3,880
                
                
                (472,500
                )
                
                (468,620
                )PROVISION
                    FOR INCOME TAXES
                
                
                -
                
                
                -
                
                
                -NET
                    LOSS
                
                $
                (3,532,789
                )
                $
                (580,633
                )
                $
                (4,113,422
                )BASIC
                    LOSS PER COMMON SHARE
                
                $
                (0.22
                )
                $
                (0.07
                )WEIGHTED
                    AVERAGE NUMBEROF
                    COMMON SHARESOUTSTANDING
                
                
                16,344,890
                
                
                8,901,594
 
 The
                    accompanying notes are an integral part of these financial
                    statements.
 22
  **CURATECH
                    INDUSTRIES, INC.**(A
                    Development Stage Company)Statements
                    of Stockholders' Equity (Deficit)
 
 DeficitAccumulatedAdditional
                
                Stock
                
                During
                    theCommon
                    Stock
                
                Paid-In
                
                Subscription
                
                DevelopmentShares
                
                Amount
                
                Capital
                
                Receivable
                
                StageBalance,
                    at inception
                
                
                -
                
                $
                -
                
                $
                -
                
                $
                -
                
                $
                -on
                    April 25, 2006Common
                    shares issued for cash
                
                
                11,495,633
                
                
                11,496
                
                
                (796
                )
                
                -
                
                
                -Common
                    shares issuedpursuant
                    to Asset PurchaseAgreement
                
                
                578,000
                
                
                578
                
                
                457,280
                
                
                -
                
                
                -Common
                    shares issued forcash
                
                
                268,606
                
                
                269
                
                
                212,688
                
                
                (55,000
                )
                
                -Recapitalization
                    pursuant toreverse
                    merger
                
                
                3,230,408
                
                
                3,230
                
                
                (2,061
                )
                
                -
                
                
                -Increase
                    in stock subscriptionsreceivable
                
                
                -
                
                
                -
                
                
                -
                
                
                -
                
                
                -Net
                    loss for the period frominception
                    on April 25, 2006through
                    December 31, 2006
                
                
                -
                
                
                -
                
                
                -
                
                
                -
                
                
                (580,633
                )Balance,
                    December 31, 2006
                
                
                15,572,647
                
                
                15,573
                
                
                667,111
                
                
                (55,000
                )
                
                (580,633
                )Common
                    shares issued for cashat
                    $1.50 per share
                
                
                317,552
                
                
                317
                
                
                510,792
                
                
                (68,250
                )
                
                -Common
                    shares issued forservices
                    at $1.50 per share
                
                
                890,000
                
                
                890
                
                
                1,334,110
                
                
                -
                
                
                -Common
                    shares issued forservices
                    at $1.01 per share
                
                
                1,800,000
                
                
                1,800
                
                
                1,816,200
                
                
                -
                
                
                -Cash
                    received on subscriptionsreceivable
                
                
                -
                
                
                -
                
                
                -
                
                
                23,998
                
                
                -Contributed
                    services
                
                
                -
                
                
                -
                
                
                7,000
                
                
                -
                
                
                -Net
                    loss for the year endedDecember
                    31, 2007
                
                
                -
                
                
                -
                
                
                -
                
                
                -
                
                
                (3,532,789
                )Balance,
                    December 31, 2007
                
                
                18,580,199
                
                $
                18,580
                
                $
                4,335,213
                
                $
                (99,252
                )
                $
                (4,113,422
                )
 
 The
                    accompanying notes are an integral part of these financial
                    statements.
  23
 **CURATECH
                      INDUSTRIES, INC.**(A
                      Development Stage Company)Statements
                      of Cash Flows
 
 For
                            theYear
                            EndedDecember
                            31,2007
                  
                  From
                                    Inceptionof
                                    theDevelopmentStage
                                    onApril
                                    25, 2006throughDecember
                                    31,2006
                  
                  From
                                  Inceptionof
                                  theDevelopmentStage
                                  onApril
                                  25, 2006throughDecember
                                  31,2007CASH
                      FLOWS FROM OPERATING ACTIVITIESNet
                      loss
                  
                  $
                  (3,532,789
                  )
                  $
                  (580,633
                  )
                  $
                  (4,113,422
                  )Adjustments
                      to reconcile net loss tonet
                      cash used by operating activities:Impairment
                      of investments
                  
                  
                  -
                  
                  
                  472,500
                  
                  
                  472,500Common
                      stock issued for services
                  
                  
                  3,153,000
                  
                  
                  -
                  
                  
                  3,153,000Services
                      contributed by shareholders
                  
                  
                  7,000
                  
                  
                  -
                  
                  
                  7,000Depreciation
                  
                  
                  1,362
                  
                  
                  -
                  
                  
                  1,362Changes
                      in operating assets and liabilities:Increase
                      in interest receivable -related
                      party
                  
                  
                  (3,880
                  )
                  
                  -
                  
                  
                  (3,880
                  )Decrease
                      in accrued expenses
                  
                  
                  (5,288
                  )
                  
                  -
                  
                  
                  (5,288
                  )Increase
                      in accounts payable
                  
                  
                  (955
                  )
                  
                  1,330
                  
                  
                  375Net
                      Cash Used byOperating
                      Activities
                  
                  
                  (381,550
                  )
                  
                  (106,803
                  )
                  
                  (488,353
                  )CASH
                      FLOWS FROM INVESTING ACTIVITIESCash
                      paid for IRT investment
                  
                  
                  -
                  
                  
                  (150,000
                  )
                  
                  (150,000
                  )Purchase
                      of fixed assets
                  
                  
                  -
                  
                  
                  -
                  
                  
                  -Net
                      Cash Used byInvesting
                      Activities
                  
                  
                  -
                  
                  
                  (150,000
                  )
                  
                  (150,000
                  )CASH
                      FLOWS FROM FINANCING ACTIVITIESCommon
                      stock issued for cash
                  
                  
                  442,859
                  
                  
                  160,700
                  
                  
                  603,559Cash
                      received in acquisition
                  
                  
                  -
                  
                  
                  137,673
                  
                  
                  137,673Cash
                      received for note payable
                  
                  
                  -
                  
                  
                  5,288
                  
                  
                  5,288Cash
                      received on subscriptions receivable
                  
                  
                  23,998
                  
                  
                  -
                  
                  
                  73,998Cash
                      paid on note payable, related party
                  
                  
                  (56,590
                  )
                  
                  (17,415
                  )
                  
                  (124,005
                  )Net
                      Cash Provided byFinancing
                      Activities
                  
                  
                  410,267
                  
                  
                  286,246
                  
                  
                  696,513NET
                      INCREASE IN CASH
                  
                  
                  28,717
                  
                  
                  29,443
                  
                  
                  58,160CASH
                      AT BEGINNING OF PERIOD
                  
                  
                  29,443
                  
                  
                  -
                  
                  
                  -CASH
                      AT END OF PERIOD
                  
                  $
                  58,160
                  
                  $
                  29,443
                  
                  $
                  58,160
 
 The
                      accompanying notes are an integral part of these financial
                      statements.
  24
  **CURATECH
                    INDUSTRIES, INC.**(A
                    Development Stage Company)Statements
                    of Cash Flows
 
 For
                          theYear EndedDecember 31,2007
                
                From
                                Inceptionof theDevelopmentStage onApril 25,
                          2006throughDecember 31,2006
                
                From
                              Inceptionof theDevelopmentStage onApril 25
                        2006,throughDecember 31,2007SUPPLEMENTAL
                    DISCLOSURES OFCASH
                    FLOW INFORMATIONCASH
                    PAID FOR:Interest
                
                $
                -
                
                $
                -
                
                $
                -Taxes
                
                $
                -
                
                $
                -
                
                $
                -NON-CASH
                    FINANCING ACTIVITIESCommon
                    stock issuedfor
                    fixed assets
                
                $
                322,500
                
                $
                322,500
                
                $
                322,500Common
                    stock issued forservices
                
                $
                3,153,000
                
                $
                -
                
                $
                3,153,000
 
 The
                    accompanying notes are an integral part of these financial
                    statements.
  25


**CURATECH
      INDUSTRIES, INC.**


(A
      Development Stage Company)


Notes
      to
      the Financial Statements (Continued)


December
      31, 2007







NOTE
              1 -
            SUMMARY
                OF SIGNIFICANT ACCOUNTING POLICIES





a.
      Organization





Curatech
      Industries, Inc. (the Company) was incorporated as a Utah Corporation in March
      2000 under the name Jump’n Jax, Inc. The Company was in the business of
      recreation equipment rentals until December 31, 2005, at which time the Company
      ceased equipment rental activities. In October 2006, the Company consummated
      an
      agreement to acquire Medacure International, Inc., a Nevada corporation.
      Pursuant to this Agreement, the Company changed its state of domicile from
      Utah
      to Nevada, and changed its corporate name to Curatech Industries, Inc. The
      Company is currently in the business of developing and marketing proprietary
      health supplements.




b.
      Accounting Method





The
      financial statements are prepared using the accrual method of accounting. The
      Company has elected a calendar year-end.





c.
      Estimates





The
      preparation of financial statements in conformity with accounting principles
      generally accepted in the United States of America requires management to make
      estimates and assumptions that affect the reported amounts of assets and
      liabilities and disclosure of contingent assets liabilities at the date of
      the
      financial statements and the reported amounts of revenues and expenses during
      the reporting period. Actual results could differ from those
      estimates.




d.
      Revenue Recognition





The
      Company earned zero revenues during the period ended December 31, 2007.
      Appropriate revenue recognition principles will be established once
      revenue-generating operations commence.





e.
      Provision for Taxes





Deferred
      taxes are provided on a liability method whereby deferred tax assets are
      recognized for deductible temporary differences and operating loss and tax
      credit carryforwards and deferred tax liabilities are recognized for taxable
      temporary differences. Temporary differences are the differences between the
      reported amounts of assets and liabilities and their tax bases. Deferred tax
      assets are reduced by a valuation allowance when, in the opinion of management,
      it is more likely than not that some portion or all of the deferred tax assets
      will not be realized. Deferred tax assets and liabilities are adjusted for
      the
      effects of changes in tax laws and rates on the date of enactment.





Net
      deferred tax assets consist of the following components as of December 31,
      2007
      and 2006:




2007
              
              2006Deferred
                  tax assets:NOL
                  Carryover
              
              $
              190,659
              
              $
              42,172Deferred
                  tax liabilities:
              
              
              -
              
              
              -Valuation
                  allowance
              
              
              (190,659
              )
              
              (42,172
              )Net
                  deferred tax asset
              
              $
              -
              
              $
              -




26














**CURATECH
      INDUSTRIES, INC.**


(A
      Development Stage Company)


Notes
      to
      the Financial Statements (Continued)


December
      31, 2007





NOTE1
              -
            SUMMARY
                OF SIGNIFICANT ACCOUNTING POLICIES
                (Continued)





e.
      Provision for Taxes (Continued)





The
      income tax provision differs from the amount of income tax determined by
      applying the U.S. federal and state income tax rates of 39% to pretax income
      from continuing operations for the period ended December 31, 2007 and 2006
      due
      to the following:


2007
              
              2006Book
                  income
              
              $
              148,487
              
              $
              226,447Impairment
                  of assets
              
              
              -
              
              
              (184,275
              )Valuation
                  allowance
              
              $
              148,487
              
              $
              42,172


f.
      Fixed
      Assets





Property
      and equipment are recorded at cost, less accumulated depreciation. Depreciation
      on equipment is determined using the straight-line method over the estimated
      useful lives (usually between three and five years) of the assets. The following
      is a summary of the Company’s major categories of fixed assets:




2007
              
              2006Office
                  equipment
              
              $
              6,811
              
              $
              6,811Accumulated
                  depreciation
              
              
              (1,362
              )
              
              -Net
                  fixed assets
              
              $
              5,449
              
              $
              6,811




g.
      Newly
      Issued Accounting Pronouncements





During
      the year ended December 31, 2007, the Company adopted the following accounting
      pronouncements:





SFAS
      No. 157, *Fair
      Value Measurements* **-** This
      Statement does not require any new fair value measurements, but rather, it
      provides enhanced guidance to other pronouncements that require or permit assets
      or liabilities to be measured at fair value. However, the application of this
      Statement may change how fair value is determined. The Statement is effective
      for financial statements issued for fiscal years beginning after November 15,
      2007, and interim periods within those fiscal years. As of December 1, 2007
      the
      FASB has proposed a one-year deferral for the implementation of the Statement
      for nonfinancial assets and nonfinancial liabilities that are recognized or
      disclosed at fair value in the financial statements on a nonrecurring basis.
      The
      implementation of this pronouncement had no material effect on the Company’s
      financial statements.





SFAS
      No. 158, *Employers’
      Accounting for Defined Benefit Pension and Other Postretirement Plans - an
      amendment of FASB Statements No. 87, 88, 106, and 132(R)* *-* This
      Statement requires that employers measure plan assets and obligations as of
      the
      balance sheet date. This requirement is effective for fiscal years ending after
      December 15, 2008. The other provisions of the Statement were effective as
      of
      the end of the fiscal year ending after December 15, 2006, for public companies.
      The implementation of this pronouncement had no material effect on the Company’s
      financial statements.




27








**CURATECH
      INDUSTRIES, INC.**


(A
      Development Stage Company)


Notes
      to
      the Financial Statements (Continued)


December
      31, 2007





NOTE
              1 -
            SUMMARY
                OF SIGNIFICANT ACCOUNTING POLICIES
                (Continued)





g.
      Newly
      Issued Accounting Pronouncements (Continued)





SFAS
      No. 159, *The
      Fair Value Option for Financial Assets and Financial Liabilities - Including
      an
      amendment of FASB Statement No. 115* *-* This
      Statement provides all entities with an option to report selected financial
      assets and liabilities at fair value. The Statement is effective as of the
      beginning of an entity’s first fiscal year beginning after November 15, 2007,
      with early adoption available in certain circumstances. The implementation
      of
      this pronouncement had no material effect on the Company’s financial
      statements.





SOP
      No. 07-01, *Clarification
      of the Scope of the Audit and Accounting Guide “Investment Companies” and
      Accounting by Parent Companies and Equity Method Investors for Investments
      in
      Investment Companies* *-* SOP
      07-01 provides guidance for determining whether an entity is within the scope
      of
      the AICPA Audit and Accounting Guide *Investment
      Companies.* The
      provisions of the SOP are effective for fiscal years beginning on or after
      December 15, 2007, with earlier application encouraged. As of December 1, 2007
      the FASB has proposed an indefinite deferral of this SOP. The implementation
      of
      this pronouncement had no effect on the Company’s financial
      statements.





*EITF
      Issue No. 06-1, Accounting for Consideration Given by a Service Provider to
      a
      Manufacturer or Reseller of Equipment Necessary for an End-Customer to Receive
      Service from the Service Provider* **-** This
      consensus concludes that if the consideration given by a service provider to
      a
      manufacturer or reseller (that is not a customer of the service provider) can
      be
      linked contractually to the benefit received by the service provider's customer,
      the service provider should account for the consideration in accordance with
      EITF Issue 01-9. The consensus is effective for the first annual reporting
      period beginning after June 15, 2007. The implementation of this pronouncement
      had no effect on the Company’s financial statements.





*EITF
      Issue No. 06-4, Accounting for Deferred Compensation and Postretirement Benefit
      Aspects of Endorsement Split-Dollar Life Insurance
      Arrangements* **-** This
      consensus concludes that for a split-dollar life insurance arrangement within
      the scope of this Issue, an employer should recognize a liability for future
      benefits in accordance with FASB Statement No. 106 (if, in substance, a
      postretirement benefit plan exists) or APB Opinion No. 12 (if the arrangement
      is, in substance, an individual deferred compensation contract) based on the
      substantive agreement with the employee. The consensus is effective for fiscal
      years beginning after December 15, 2007, with early application permitted.
      The
      implementation of this pronouncement had no effect on the Company’s financial
      statements.





*EITF
      Issue No. 06-8, Applicability of the Assessment of a Buyer's Continuing
      Investment under FASB Statement No. 66, “Accounting for Sales of Real Estate”,
      for Sales of Condominiums* **-** This
      consensus concludes that an entity is required to evaluate the adequacy of
      a
      buyer’s initial and continuing investment for purposes of determining whether it
      is appropriate to recognize profit from a real estate sale involving a
      condominium unit or time-sharing interest under the percentage-of-completion
      method under Statement No. 66. The consensus is effective for the first annual
      reporting period beginning after March 15, 2007. The implementation of this
      pronouncement had no effect on the Company’s financial statements.





*EITF
      Issue No. 06-10, Accounting for Collateral Assignment Split-Dollar Life
      Insurance Arrangements* **-** In
      this
      Issue, a consensus was reached that an employer should recognize a liability
      for
      the postretirement benefit related to a collateral assignment split-dollar
      life
      insurance arrangement in accordance with either FASB Statement No. 106 or APB
      Opinion No. 12, as appropriate, if the




28




**CURATECH
      INDUSTRIES, INC.**


(A
      Development Stage Company)


Notes
      to
      the Financial Statements (Continued)


December
      31, 2007





NOTE
              1 -
            SUMMARY
                OF SIGNIFICANT ACCOUNTING POLICIES
                (Continued)





g.
      Newly
      Issued Accounting Pronouncements (Continued)





employer
      has agreed to maintain a life insurance policy during the employee's retirement
      or provide the employee with a death benefit based on the substantive agreement
      with the employee. A consensus also was reached that an employer should
      recognize and measure an asset based on the nature and substance of the
      collateral assignment split-dollar life insurance arrangement. The consensuses
      are effective for fiscal years beginning after December 15, 2007, including
      interim periods within those fiscal years, with early application permitted.
      The
      implementation of this pronouncement had no effect on the Company’s financial
      statements.





*EITF
      Issue No. 06-11, Accounting for Income Tax Benefits of Dividends on Share-Based
      Payment Awards* **-** In
      this
      Issue, a consensus was reached that a realized income tax benefit from dividends
      or dividend equivalents that are charged to retained earnings and are paid
      to
      employees for equity-classified nonvested equity shares, nonvested equity share
      units, and outstanding equity share options should be recognized as an increase
      in additional paid-in capital. This Issue should be applied prospectively to
      the
      income tax benefits that result from dividends on equity-classified employee
      share-based payment awards that are declared in fiscal years beginning after
      December 15, 2007, and interim periods within those fiscal years. Early
      application is permitted. The implementation of this pronouncement had no effect
      on the Company’s financial statements.





*EITF
      Issue No. 07-3, Accounting for Nonrefundable Advance Payments for Goods or
      Services Received for Use in Future Research and Development
      Activities* **-** In
      this
      Issue, a consensus was reached that *nonrefundable* advance
      payments for future research and development activities should be deferred
      and
      capitalized. This Issue is effective for financial statements issued for fiscal
      years beginning after December 15, 2007, and interim periods within those fiscal
      years. Early application is not permitted. The implementation of this
      pronouncement had no effect on the Company’s financial statements.





*FSP
      No. FAS 158-1, Conforming Amendments to the Illustrations in FASB Statements
      No.
      87, No. 88, and No. 106 and to the Related Staff Implementation
      Guides* **-** This
      FSP
      provides conforming amendments to the illustrations in FASB Statements No.
      87,
      88, and 106 and to related staff implementation guides as a result of the
      issuance of FASB Statement No. 158. The conforming amendments made by this
      FSP
      are effective as of the effective dates of Statement No. 158. The unaffected
      guidance that this FSP codifies into Statements No. 87, 88, and 106 does not
      contain new requirements and therefore does not require a separate effective
      date or transition method. The implementation of this pronouncement had no
      effect on the Company’s financial statements.





*FSP
      No. FIN 39-1, Amendment of FASB Interpretation No. 39* *-* This
      FSP
      amends FASB Interpretation (FIN) No. 39, *Offsetting
      of Amounts Related to Certain Contracts,* to
      permit
      a reporting entity to offset fair value amounts recognized for the right to
      reclaim cash collateral or the obligation to return cash collateral against
      fair
      value amounts recognized for derivative instruments executed with the same
      counterparty under the same master netting arrangement that have been offset
      in
      accordance with paragraph 10 of FIN 39. The guidance in this FSP is effective
      for fiscal years beginning after November 15, 2007, with early application
      permitted. The implementation of this pronouncement had no effect on the
      Company’s financial statements.





*FSP
      No. FIN 46(R)-7, Application of FASB Interpretation No. 46(R) to Investment
      Companies* **-** This
      FSP
      addresses the application of FASB Interpretation (FIN) No. 46 (revised December
      2003), *Consolidation
      of Variable Interest Entities* ,
      by an
      entity that accounts for its investments in accordance with the specialized
      accounting guidance in the AICPA Audit and Accounting Guide, *Investment
      Companies* .
      The
      provisions of the FSP are effective when the entity adopts SOP 07-01. The
      implementation of this pronouncement had no effect on the Company’s financial
      statements.




29





**CURATECH
      INDUSTRIES, INC.**


(A
      Development Stage Company)


Notes
      to
      the Financial Statements (Continued)


December
      31, 2007





NOTE
              1 -
            SUMMARY
                OF SIGNIFICANT ACCOUNTING POLICIES
                (Continued)





g.
      Newly
      Issued Accounting Pronouncements (Continued)




*SEC
      Staff Accounting Bulletin No. 109, Written Loan Commitments Recorded at Fair
      Value Through Earnings* ***-*** SAB
      109
      expresses the current view of the staff that the expected net future cash flows
      related to the associated servicing of the loan should be included in the
      measurement of all written loan commitments that are accounted for at fair
      value
      through earnings.  SEC registrants are expected to apply the views in
      Question 1 of SAB 109 on a prospective basis to derivative loan commitments
      issued or modified in fiscal quarters beginning after December 15, 2007. The
      implementation of this pronouncement had no effect on the Company’s financial
      statements.




NOTE
              2 -
            GOING
                CONCERN





The
      Company's financial statements are prepared using accounting principles
      generally accepted in the United States of America applicable to a going concern
      which contemplates the realization of assets and liquidation of liabilities
      in
      the normal course of business. The Company has not established revenues
      sufficient to cover its operating costs and allow it to continue as a going
      concern. Management intends to increase operations through expanding its
      operations into other locals, in the interim, management and primary
      shareholders are committed to meeting the Company minimal operating
      expenses.




NOTE
              3 -
            COMMON
                STOCK TRANSACTIONS





On
      April
      28, 2006, the Company issued an aggregate of 11,495,633 shares of common stock
      to various individuals, each of whom was an officer and/or director of the
      Company on the date of issuance, in exchange for an aggregate of $10,700 in
      cash.





On
      April
      28, 2006, the Company issued an aggregate of 11,495,633 shares of common stock
      to various individuals, each of whom was an officer and/or director of the
      Company on the date of issuance, in exchange for an aggregate of $10,700 in
      cash.





On
      May
      12, 2006, the Company issued an aggregate of 578,000 shares of common stock
      to
      two unrelated individuals, as partial payment for Immune Response Therapy assets
      (see Note 4).





On
      May
      15, 2006, the Company issued 268,606 shares of common stock to an unrelated
      third party in exchange for $150,000 in cash. Of this amount, $55,000 remained
      uncollected as of December 31, 2006, and has been recorded as stock
      subscriptions receivable.





During
      the year ended December 31, 2007 the Company issued 317,552 shares of common
      stock for cash and subscriptions receivable at $1.50 per share. In addition,
      the
      Company issued 1,800,000 shares of common stock for services rendered at $1.01
      per share.





NOTE
              4 -
            RELATED
                PARTY TRANSACTIONS





During
      the period from inception through December 31, 2007 the Company has at various
      times made temporary loans to the Company’s Chief Executive Officer. The
      outstanding balance of these loans at December 31, 2007, including accrued
      interest, is $77,885.




30




**CURATECH
      INDUSTRIES, INC.**


(A
      Development Stage Company)


Notes
      to
      the Financial Statements (Continued)


December
      31, 2007





NOTE
              5 -
            AGREEMENT
                AND PLAN OF MERGER





On
      October 26, 2006, the Company entered into an Acquisition Agreement with Jump’n
      Jax, Inc. (“Jump’n Jax”). The acquisition was consummated pursuant to an
      agreement entered into on June 22, 2006, whereby the Company agreed to merge
      into Jump’n Jax’s newly created, wholly-owned subsidiary, CuraTech Acquisitions,
      Inc., with the Company being the surviving entity as Jump’n Jax’s wholly owned
      operating subsidiary.





Prior
      to
      completion of the acquisition on October 4, 2006, the Jump’n Jax completed a
      forward stock split, on a four shares for one share basis. In addition, Jump’n
      Jax changed its corporate name to CuraTech Industries, Inc. As a result of
      the
      forward stock split, Jump’n Jax’s outstanding shares of common stock increased
      from 807,602 shares to 3,230,408 shares. The Company also changed its corporate
      domicile from the State of Utah to Nevada. Additionally, per the terms of the
      Merger Agreement the Jump’n Jax issued an aggregate of 12,342,239 shares of its
      common stock, post-split, to the stockholders of the Company. Also, the Company
      added three new directors, each nominated by MedaCure, to its Board of
      Directors. Upon completion of the Acquisition, approximately 58.9% of the
      Company’s common stock is beneficially owned together by the Dastrup family.
      Accordingly, this group has the capability to substantially control the vote
      on
      all significant matters pertaining to the Company without the approval of
      shareholders.





The
      Company accounted for this transaction as a reverse-acquisition, with MedaCure
      presented as the accounting acquirer. Therefore, the historical financial
      statements presented herein reflect only those of MedaCure, the accounting
      acquirer, since its inception on April 25, 2006. The reverse-acquisition is
      presented as a recapitalization of Medacure. Accordingly, the historical
      stockholders’ equity (deficit) of MedaCure prior to the acquisition transaction
      has been retroactively restated pursuant to SFAS 141.





From
      the
      consummation of the Merger Agreement, the Company has begun the development
      and
      bringing to market a certain health supplement that is intended to enhance
      and
      build-up the body’s natural immune system defenses. The Company intends to
      commence commercial marketing of its supplement in the near future primarily
      outside the U.S. Initial marketing in the U.S. will primarily be to the
      veterinarian market for use in treating animals. The Company also intends to
      initiate a collaboration and partnering program that will focus on developing
      business alliances designed to generate sales, applications and marketing
      opportunities.





NOTE
      6 -  ASSET
      PURCHASE AGREEMENT





On
      May
      15, 2006 the Company entered into an Asset Purchase Agreement whereby the
      Company acquired certain exclusive proprietary Immune Response Therapy (“IRT”)
      products and technologies from Dr. William and Freida Stacey, in exchange for
      $150,000 in cash and 537,500 shares of the Company’s common stock. The shares in
      this transaction have been valued at $0.60 per share, or $322,500, bringing
      the
      total value of the consideration paid by the Company for the IRT assets to
      $472,500.





To
      the
      date of these financial statements, the Company has yet to realize significant
      revenues from the utilization of the IRT assets. The Company’s management
      continues to focus its business strategy on the utilization of the IRT assets.
      However, due to the fact that no significant revenues have been generated from
      the IRT assets, the Company has fully impaired the IRT assets as of December
      31,
      2006. Accordingly, the Company has recognized an asset impairment expense of
      $472,500 for the period ended December 31, 2006.




31







**Item
                8.**
            **Changes
                in and Disagreements with Accountants on Accounting and****Financial
                Disclosure**








(a)
      On
      March 31, 2006, HJ & Associates, LLC was terminated as the certifying
      accountant for the Company (the "Registrant").





HJ
&
      Associates, LLC served from the inception of the Company as the certifying
      accountant for the Company’s financial statements. From the date on which HJ
& Associates, LLC was engaged until the date HJ & Associates, LLC was
      terminated, there were no disagreements with HJ & Associates, LLC on any
      matter of accounting principles or practices, financial statement disclosure,
      or
      auditing scope or procedure, which disagreements, if not resolved to the
      satisfaction of HJ & Associates, LLC would have caused HJ & Associates,
      LLC to make reference to the subject matter of the disagreements in connection
      with any reports it would have issued, and there were no "reportable events"
      as
      that term is defined in Item 304(a)(1)(iv) of Regulation S-B.





(b)
      On
      March 29, 2006, the Company entered into an engagement letter with Moore &
Associates, Chartered **** to
      assume
      the role of its new certifying accountant. Moore & Associates,
      Chartered **** w as
      asked
      to audit the year ended December 31, 2006 and subsequent years. During the
      two
      most recent fiscal years and the subsequent interim periods prior to the
      engagement of Moore & Associates, Chartered, the Company did not consult
      with Moore & Associates, Chartered, with regard to:





(i)
      the
      application of accounting principles to a specified transaction, either
      completed or proposed; or the type of audit opinion that might be rendered
      on
      the Company's financial statements; or





(ii)
      any
      matter that was either the subject of a disagreement or a reportable event
      (as
      described in Item 304(a)(1)(iv) of Regulation S-B).





The
      engagement of the new principal auditor was recommended and approved by the
      Company’s Board of Directors.







**Item
                8A.**
            **Controls
                and Procedures**







The
      Company’s president acts both as the Company’s chief executive officer and chief
      financial officer and is responsible for establishing and maintaining disclosure
      controls and procedures for the Company.





Evaluation
      of disclosure controls and procedures.





Under
      the
      supervision and with the participation of management, Lincoln M. Dastrup, acting
      as our chief executive officer and chief financial officer, evaluated the
      effectiveness of the design and operation of our disclosure controls and
      procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities
      Exchange Act of 1934 (“Exchange Act”), as of December 31, 2007. Based on this
      evaluation, our chief executive officer and chief financial officer concluded
      that, as of the end of the period covered by this report, our disclosure
      controls and procedures were not effective to ensure that the information
      required to be disclosed by us in the reports we submit under the Exchange
      Act
      is recorded, processed, summarized and reported within the time periods
      specified in the applicable rules and forms and that such information was
      accumulated and communicated to our chief executive officer and chief financial
      officer, in a manner that allowed for timely decisions regarding required
      disclosure ,
      for the
      following reason:





-
      we
      overlooked the inclusion of our management’s annual report on internal control
      over financial reporting in our initial annual report filed on Form 10-KSB
      for
      the year ended December 31, 2007, and as a result we determined that we had
      a
      material weakness in our ability to determine certain changes in the laws that
      affect our disclosure obligations.




32




We
      are
      developing a plan to ensure that we are aware of changes in the laws that affect
      our disclosure obligations, to ensure that all information required to be
      disclosed by us in the reports we submit under the Exchange Act is recorded,
      processed, summarized and reported accurately and timely. As of the date of
      this
      amended report, we have taken the following steps to address the material
      weakness in our disclosure controls and procedures:





1.
            Before
                each report is prepared, we will review the Commission’s website,www.sec.gov,
                in an effort to determine any recent changes in the laws affecting
                our
                disclosure obligations; and


2.
            As
                each report is prepared, we will discuss with our independent consultants
                who assist us in the preparation of the reports and financial statements
                included within the reports whether they are aware of any recent
                changes
                in the laws affecting our disclosure
                obligations.





The
      remainder of our plan involves seeking additional training of existing personnel
      in the area of SEC reporting issues and/or, to the extent deemed necessary,
      the
      possible hiring of personnel or outside consultants who are familiar and
      conversant with SEC reporting issues.





Management’s
      Annual Report on Internal Control Over Financial Reporting





Our
      management is responsible for establishing and maintaining adequate internal
      control over financial reporting, as such term is defined in Rules 13a-15(f)
      and
      15d-15(f) of the Exchange Act. Our internal control system was designed to
      provide reasonable assurance regarding the reliability of financial reporting
      and the preparation of financial statements for external purposes, in accordance
      with generally accepted accounting principles. Because of inherent limitations,
      a system of internal control over financial reporting may not prevent or detect
      misstatements. Therefore, even those systems determined to be effective can
      provide only reasonable, not absolute, assurance of achieving their control
      objectives. Also, projections of any evaluation of effectiveness to future
      periods are subject to the risk that controls may become inadequate due to
      change in conditions, or that the degree of compliance with the policies or
      procedures may deteriorate.





Our
      management, including our principal executive officer and principal accounting
      officer, conducted an evaluation of the effectiveness of our internal control
      over financial reporting using the criteria set forth by the Committee of
      Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control
      -Integrated Framework. Based upon this evaluation, our management, including
      the
      Chief Executive Officer and Principal Financial Officer, has concluded that
      our
      internal controls over financial reporting were effective as of December 31,
      2007.





During
      the quarter ended December 31, 2007, there has been no change in our internal
      controls over financial reporting (as defined in Rules 13a-15 and 15d-15 under
      the Exchange Act) that has materially affected, or is reasonably likely to
      materially affect, our internal controls over financial reporting.





This
      annual report does not include an attestation report of the Company’s registered
      public accounting firm regarding internal control over financial reporting.
      Management’s report was not subject to attestation by the Company’s registered
      public accounting firm pursuant to temporary rules of the SEC that permit the
      Company to provide only the management’s report in this annual
      report.








**Item
      8B. Other Information**








Not
      applicable.




33




**PART
      III**








**Item
              9.**
            **Directors,
                Executive Officers, Promoters and Control Persons;****Compliance
                with Section 16(a) of the Exchange
                Act**





**Identification
      of directors and executive officers**





Upon
      completion of the MedaCure acquisition, our former President, Lane S. Clissold
      submitted his resignation as a director and President. Steven D. Moulton
      remained on the board of directors until January 4, 2007, when he resigned.
      In
      accordance with the provisions of the acquisition, MedaCure appointed three
      new
      directors, Lincoln Dastrup, Linda L. Dastrup and Jarom Dastrup, to serve on
      the
      board of directors. Lincoln Dastrup was elected CEO. Jarom Dastrup was elected
      Executive Vice President and Secretary, and Linda L. Dastrup was elected
      Treasurer. The following persons currently serve as directors and executive
      officers.




**Name**
            
            **Age**
            
            **Position**Lincoln
                Dastrup
            
            53
            
            CEO,
                CFO and DirectorJarom
                Dastrup
            
            28
            
            Executive
                Vice President, Secretary and DirectorLinda
                L. Dastrup
            
            49
            
            Treasurer
                and Director




All
      directors hold office until the next annual meeting of stockholders and until
      their successors have been duly elected and qualified. There are no agreements
      with respect to the election of directors. We have not compensated directors
      for
      service on the board of directors or any committee thereof, but directors are
      entitled to be reimbursed for expenses incurred for attendance at meetings
      of
      the board and any committee of the board. Officers are appointed annually by
      the
      board and each executive officer serves at the discretion of the board. We
      do
      not have any standing committees.





Currently,
      there is no arrangement, agreement or understanding between management and
      non-management stockholders under which non-management stockholders may directly
      or indirectly participate in or influence the management of our affairs. Present
      management openly accepts and appreciates any input or suggestions from
      stockholders. However, the board is elected by the stockholders and the
      stockholders have the ultimate say in who represents them on the board. There
      are no agreements or understandings for any officer or director to resign at
      the
      request of another person and none of the current offers or directors are acting
      on behalf of, or will act at the direction of any other person.





The
      business experience of each of the persons listed above during the past five
      years is as follows:





***Lincoln
      Dastrup.*** Mr.
      Dastrup has served as a director and as CEO and CFO of the Company since October
      2006. Mr. Dastrup has over 26 years of experience in investment banking,
      corporate development, management, marketing and manufacturing with public
      companies. Since 1995, he has been semi-retired and primarily manages his
      personal investments. In 1989, Mr. Dastrup co-founded CIMETRIX Incorporated,
      an
      international robotics firm. Mr. Dastrup served as the President and CEO of
      CIMETRIX until 1995. In 1986 Mr. Dastrup founded Corporate Funding, a venture
      capital firm. Prior to that Mr. Dastrup was the founder, President and CEO
      of
      Barron, Marshal, & Kaman, a New York based investment banking firm, and
      members of the New York Stock Exchange. In 1979 Mr. Dastrup was a co-founder
      of
      Universal Fashions Originals, a company engaged in the business of clothing
      manufacturing and design. In 1980, Universal Fashions merged with an
      over-the-counter public company. After the merger, Mr. Dastrup served as a
      director, executive vice-president and president of its wholly-owned subsidiary,
      Classic Covers, Inc. Since 1980, Mr. Dastrup has participated in over 14 mergers
      and acquisitions and has financed seven companies.





***Linda
      L. Dastrup*** .
      Mrs.
      Dastrup has served as a director and as Treasurer of the Company since October
      2006. Mrs. Dastrup has over 20 years of experience in corporate development,
      management and manufacturing with public companies. Since 1995, she has been
      semi-retired and primarily manages her personal investments. In 1989, Mrs.
      Dastrup co-founder CIMETRIX Incorporated, an International robotics firm. Mrs.
      Dastrup was a key contributor to the original buy/sale and royalty agreement
      of
      CIMETRIX Incorporated. She served as an executive officer of CIMETRIX for over
      5
      years. Prior to that Mrs. Dastrup was a Director and Treasurer of Barron,
      Marshal, & Kaman, a New York based Investment Banking firm, and members of
      the New York Stock Exchange. In 1979 Mrs. Dastrup was a co-founder of Universal
      Fashions Originals, a Company engaged in the business of clothing manufacturing
      and design. In 1980 Universal Fashions merged with an over-the-counter public
      Company. Mrs. Dastrup’s responsibilities included that of all manufacturing and
      design. Mrs. Dastrup is the wife of Lincoln Dastrup.




34





***Jarom
      L. Dastrup*** **.** Mr.
      Dastrup has servied as a director and as Executive Vice President and Secretary
      of the Company since October 2006. Mr. Dastrup has over 5 years of experience
      in
      corporate development, and administration. Since 2005, Mr. Dastrup has been
      a
      private money advisor and manager. In 2006 Mr. Dastrup was co-founder and
      Manager of Vastmann Investment Partners, LLC, a private equity fund. Currently
      Mr. Dastrup is responsible for all client relations, client accounts, client
      investments, and all company finances. Prior to that Mr. Dastrup managed a
      portfolio of stocks, options, and futures. In 2002 Mr. Dastrup was a partner
      in
      and managed The Iceberg Drive-In, a Utah based fast food restaurant. Mr. Dastrup
      graduated from Utah Valley State College where he received his Bachelor Degree
      in Business Management. Mr. Dastrup is the son of Lincoln and Linda
      Dastrup.





**Significant
      employees**





Curatech
      Industries, Inc. and its subsidiary have no present employees who are expected
      to make a significant contribution to the Company’s business other than the
      Company’s current officers and directors. It is expected that current members of
      management will be the only persons whose activities will be material to the
      Company’s operations.





**Family
      relationships**





There
      are
      no family relationships between any directors or executive officers of the
      Company and/or the officers, directors or managers of its subsidiary, MedaCure,
      either by blood or by marriage, except for the following: Lincoln Dastrup and
      Linda L. Dastrup are husband and wife. Jarom Dastrup is their son.





**Involvement
      in certain legal proceedings**





During
      the past five years, no present or former director, person nominated to become
      a
      director, executive officer, promoter or control person of the
      Company:





(1)
      was a
      general partner or executive officer of any business which filed a petition
      in
      bankruptcy or against which any bankruptcy petition was filed, either at the
      time of the bankruptcy or two years prior to that time;





(2)
      was
      convicted in a criminal proceeding or named subject to a pending criminal
      proceeding (excluding traffic violations and other minor offenses);





(3)
      was
      subject to any order, judgment or decree, not subsequently reversed, suspended
      or vacated, of any court of competent jurisdiction, permanently or temporarily
      enjoining, barring, suspending or otherwise limiting his involvement in any
      type
      of business, securities or banking activities; or





(4)
      was
      found by a court of competent jurisdiction (in a civil action), the Securities
      and Exchange Commission or the Commodity Futures Trading Commission to have
      violated a federal or state securities or commodities law, and the judgment
      has
      not been reversed, suspended or vacated.




35





**Section
      16(a) beneficial ownership reporting compliance**





Based
      solely upon a review of Forms 3 and 4 furnished to the Company under Rule
      16a-3(d) during its most recent fiscal year, the Company knows of no person
      who
      was a director, officer, beneficial owner of more than ten percent of any class
      of equity securities of the Company registered pursuant to Section 12
      ("Reporting Person") that failed to file on a timely basis any reports required
      to be furnished pursuant to Section 16(a) during the most recent fiscal year,
      except for the following:





(1)
      On
      September 17, 2007, The Dastrup Family Trust sold 600,000 shares of the
      Company’s common stock. The Dastrup Family Trust, Lincoln Dastrup and Linda L.
      Dastrup should each have filed a Form 4 Report concerning this transaction
      within two business days following the transaction. The reports have not yet
      been filed.





(2)
      On
      November 30, 2007, The Dastrup Family Trust sold 375,000 shares of the Company’s
      common stock. The Dastrup Family Trust, Lincoln Dastrup and Linda L. Dastrup
      should each have filed a Form 4 Report concerning this transaction within two
      business days following the transaction. The reports have not yet been
      filed.





(3)
      On
      December 15, 2007, the Company issued 1,000,000 shares of the Company’s common
      stock to The Dastrup Family trust for services rendered at a value of $1.01
      per
      share. The Dastrup Family Trust, Lincoln Dastrup and Linda L. Dastrup should
      each have filed a Form 4 Report concerning this transaction within two business
      days following the transaction. The reports have not yet been
      filed.




36








**Item
                10.**
            **Executive
                Compensation**








**Cash
      compensation**





The
      following table sets forth the aggregate compensation paid by the Company and/or
      its subsidiaries to the Company’s Chief Executive Officer and to any other
      officer, director or employee who received $100,000 or more during any of the
      last three fiscal years:




**SUMMARY
      COMPENSATION TABLE**





Long
                Term CompensationAnnual
                CompensationAwards
            
            Payouts(a)
            
            (b)
            
            (c)
            
            (d)
            
            (e)
            
            (f)
            
            (g)
            
            (h)
            
            (i)Name
                and
              Principal
              Position
            
            Year
                or Period
              Ended
            
            Salary
              ($)
            
            Bonus
              ($)
            
            Other
              Annual
              Compen
            
            Restricted
              Stock
            
            Secur-
              ities
              Under-lying
              Options
            
            LTIP
              Pay-
              outs
            
            All
              Other
              Compen-
              sationLincolnDastrup(1)
            
            
            12/31/07
            
            $
            0
            
            
            0
            
            
            0
            
            
            0
            
            
            0
            
            
            0
            
            $
            1,010,000LincolnDastrup(2)
            
            
            12/31/06
            
            $
            17,800
            
            
            0
            
            
            0
            
            
            0
            
            
            0
            
            
            0
            
            
            0LaneClissold(2)
            
            
            12/31/06
            
            $
            0
            
            
            0
            
            
            0
            
            
            0
            
            
            0
            
            
            0
            
            
            0LaneClissold
            
            
            12/31/05
            
            $
            0
            
            
            0
            
            
            0
            
            
            0
            
            
            0
            
            
            0
            
            
            0 ________________


(1)
      The
      Company issued 1,000,000 shares of its common stock, valued at $1.01 per share,
      to The Dastrup Family Trust in 2007 for services rendered.


(2)
      Lane
      Clissold served as CEO until October 2006 when Lincoln Dastrup became
      CEO.





Except
      as
      described above, no cash compensation, deferred compensation or long-term
      incentive plan awards were issued or granted to the Company’s management during
      the fiscal years ended December 31, 2007, 2006 or 2005. Except as described
      above, no other officers or directors were paid any salaries or compensation
      during the year ended December 31, 2007. Further, no member of the Company’s
      management has been granted any option or stock appreciation rights.
      Accordingly, no tables relating to such items have been included within this
      Item 10.





There
      are
      no present plans whereby the Company will issue any of its securities to
      management, promoters, their affiliates or associates in consideration of
      services rendered or otherwise, except as described herein.





**Compensation
      of directors**





The
      Company has no arrangement for compensating its directors for their services
      as
      directors or for serving on any committees. However, directors may be
      compensated for services which they render as officers and/or as employees
      of
      the Company.





**Employment
      contracts and termination of employment and change-in-control** **arrangements**





There
      are
      no employment contracts, compensatory plans or arrangements, including payments
      to be received from the
      Company with
      respect to any executive officer of the Company which would in any way result
      in
      payments to any such person because of his or her resignation, retirement or
      other termination of employment with the Company or its subsidiary, any change
      in control of the Company or a change in the person's responsibilities following
      a change in control of the Company.




37





Nor
      are
      there any agreements or understandings for any director or executive officer to
      resign at the request of another person. None of the Company’s directors or
      executive officers is acting on behalf of or will act at the direction of any
      other person.





The
      Company may enter into employment agreements with some of its officers in the
      near future but no definite terms have been agreed to yet.





**Compensation
      pursuant to plans; pension table**





There
      were no stock awards, restricted stock awards, stock options, stock appreciation
      rights, long-term incentive plan compensation or similar rights granted to
      any
      of our officers or directors. None of our officers or directors presently holds
      directly any stock options or stock purchase rights. We have no retirement,
      pension, profit sharing, or other plan covering any of our officers and
      directors.





We
      have
      adopted no formal stock option plans for our officers, directors and/or
      employees. We reserve the right to adopt one or more stock options plans in
      the
      future. Presently we have no plans to issue additional shares of our common
      or
      preferred stock or options to acquire the same to our officers, directors or
      their affiliates or associates.





**Other
      compensation**


No





**Item
                11.**
            **Security
                Ownership of Certain Beneficial Owners and Management and****Related
                Stockholder Matters**





The
      following table sets forth the share holders of those persons who are known
      to
      the Company to be the beneficial owners of more than five percent (5.0%) of
      the
      Company’s common stock and of the share holdings of the Company’s directors and
      executive officers as of April 14, 2008. Each of these persons has sole
      investment and sole voting power over the shares indicated.





All
      share
      amounts and percentages have been adjusted to reflect the four shares for one
      (4
      for 1) share forward stock split and the issuance of shares for the MedaCure
      acquisition. Percentages are based on 18,555,199 shares issued and outstanding.




**Name
                and Address**
            
            **Number
                of Shares**
            
            **Percent****(1)***5%
                Beneficial Owners*:The
                Dastrup Family Trust
            
            
            7,936,673
            (2)
            
            42.8
            %*Directors
                and Executive Officers*:Lincoln
                Dastrup
            
            
            7,936,673
            (3)
            
            42.8
            %Linda
                Dastrup
            
            
            7,936,673
            (4)
            
            42.8
            %Jarom
                Dastrup
            
            
            1,986,667
            (5)
            
            10.7
            %All
                directors and executive officers as a group
            
            
            9,923,340
            (6)
            
            53.5
            %(3
                persons)








38








(1)
            Percentage
                ownership is based on 18,555,198 shares outstanding. Percentage is
                calculated for each individual listed based upon their beneficial
                ownership of shares, although ownership may be shared with others,
                such as
                the Dastrup Family Trust.(2)
            The
                Dastrup Family Trust is a family trust of which Lincoln Dastrup and
                Linda
                Dastrup are the trustees with voting and dispositive power over the
                trust.








(3)
            Mr.
                Dastrup’s shares are held in the name of The Dastrup Family Trust, of
                which Mr. Dastrup is a trustee and, as indicated above, and which
                holds
                7,936,673 shares.(4)
            Mrs.
                Dastrup’s shares are held in the name of The Dastrup Family Trust, of
                which Mrs. Dastrup is a trustee and, as indicated above, and which
                holds
                7,936,673 shares.





(5)
            Amount
                shown includes 886,667 shares that are owned by Vastmann Investment
                Partners, LLC, of which Jarom Dastrup owns a one-third interest,
                and over
                which he has voting and dispositive control.(6)
            Amount
                shown represents the holdings of The Dastrup Family Trust, of which
                Lincoln Dastrup and Linda Dastrup are trustees, Jarom Dastrup and
                Vastmann
                Investment Partners, LLC that is one-third owned by Jarom
                Dastrup.





All
      common shares held by the officers, directors and principal shareholders listed
      above are A restricted
      or control securities @ and are
      subject to limitations on resale. The shares may be sold in compliance with
      the
      requirements of Rule 144, after a minimum one year holding period has been
      met.





Rule
      13d-3 generally provides that beneficial owners of securities include any person
      who directly or indirectly has or shares, voting power and/or investment power
      with respect to such securities; and any person who has the right to acquire
      beneficial ownership of such security within 60 days.





Any
      securities not outstanding which are subject to options, warrants or conversion
      privileges exercisable within 60 days are treated as outstanding for the purpose
      of computing the percentage of outstanding securities owned by that person.
      But
      such securities are not treated as outstanding for the purpose of computing
      the
      percentage of the class owned by any other person.





**Changes
      in control**





There
      are
      no present arrangements or pledges of the Company’s securities, known to
      management, which may result in a change in control of the Company.








**Item
                12.**
            **Certain
                Relationships and Related
                Transactions**








**Transactions
      with management and others**





Except
      as
      indicated below, and for the periods indicated, there were no material
      transactions, or series of similar transactions, during the last three fiscal
      years ended December 31, 2007, or since December 31, 2007, or any currently
      proposed transactions, or series of similar transactions, to which the Company
      was or is to be party, in which the amount involved exceeds the lesser of
      $120,000 or one percent of the average of the company’s total assets at year-end
      for the last three fiscal years, and in which any director or executive officer,
      or any security holder who is known by the Company to own of record or
      beneficially more than 5% of any class of the Company's common stock, or any
      member of the immediate family of any of the foregoing persons, has an interest,
      other than the following:




39





(1)
      On
      May 20, 2005, the board of directors authorized the issuance of a total of
      1,333,336 post-split shares (“the issuance”) of common stock, separately, to
      Lane S. Clissold (666,668) and Steven D. Moulton (666,668), two of the Company’s
      former officers. The shares were issued in consideration for Messrs. Clissold's
      and Moulton's agreement to convert into shares of common stock all amounts
      due
      and owing to them resulting from loans and/or advances made to the Company.
      As a
      result of the issuance, the loans and/or advances made by Messrs. Clissold
      and
      Moulton to the Company through May 15, 2005, and all accrued interest thereon,
      were deemed to be paid in full. The shares were valued at $0.1935 per share
      for
      total consideration of $64,500





(2)
      In
      October 2006 the Company issued an aggregate of approximately 12,342,239 shares
      of common stock as consideration for the acquisition of Medacure International,
      Inc.





(3)
      During the years ended December 31, 2007 and 2006 the Company has at various
      times made temporary loans to the Company’s Chief Executive Officer. The
      outstanding balance of these loans at December 31, 2007, including accrued
      interest, is $77,885.





(4)
      On
      December 15, 2007, the Company issued 1,000,000 shares of its common stock,
      valued at $1.01 per share, to The Dastrup Family Trust for services rendered
      to
      the Company. Lincoln M. Dastrup and Linda L. Dastrup are Trustees of The Dastrup
      Family trust. Mr. and Mrs. Dastrup and their five children are beneficiaries
      of
      the trust.





**Potential
      Conflict of Interest**





We
      have
      no formal conflict of interest policy in place regarding the possibility of
      our
      entering into transactions with affiliates. We lack such a policy because we
      believe it highly unlikely that we will acquire or do business with an entity
      in
      which members of our management have an ownership interest, directly or
      indirectly. However, in the event a related party transaction did arise, it
      would almost certainly be ratified by a disinterested board of directors and,
      possibly, by the stockholders if deemed necessary. Management intends do
      whatever is necessary to fully and completely comply with Nevada corporate
      law
      relating to conflicting interest transactions as set forth in the Nevada Revised
      Statutes.




40








**Item
      13. Exhibits**








Exhibit
              No.
            Exhibit
                Name





2.1(1)
            
            Agreement
                and Plan of Merger by and among Jump’n Jax, Inc., CuraTech Acquisitions,
                Inc. and MedaCure International, Inc., including
                Addendum


3.1(2)
            
            Articles of
              Incorporation


3.2(2)
            
            By-Laws


21.1(3)
            
            List of
              Subsidiaries


31.1
            
            Certification
                of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley
                Act of 2002


31.2
            
            Certification
                of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley
                Act of 2002


32.1
            
            Certificate
                of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley
                Act of 2002


32.2
            
            Certificate
                of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley
                Act of 2002


Summaries
                of all exhibits contained within this report are modified in their
                entirety by reference to these
                exhibits.


_________________


(1)
            Exhibit
                2.1 is incorporated by reference from the Company’s Form 8-K Current
                Report filed June 22, 2006 as Exhibit
                2.1


(2)
            Exhibit
                3.1 and 3.2 are incorporated by reference from the Company’s SB-2
                Registration Statement filed September 9, 2004 as Exhibits 3.1 and
                3.2


(3)
            Exhibit
                21.2 is incorporated by reference from the Company’s Form 8-K Current
                Report filed December 21, 2006








**Item
      14. Principal Accountants Fees and Services**








We
      do not
      have an audit committee and as a result our entire board of directors performs
      the duties of an audit committee. Our board of directors will approve in advance
      the scope and cost of the engagement of an auditor before the auditor renders
      audit and non-audit services. As a result, we do not rely on pre-approval
      policies and procedures.





**Audit
      Fees**





The
      aggregate fees billed by our independent auditors of record, Moore &
Associates, for professional services rendered for the quarterly reviews of
      our
      financial statements during 2006 and for the audit of our annual financial
      statements included in our report on Form 10-KSB for the year ended December
      31,
      2006 were approximately $9,131.00. The aggregate fees billed by our independent
      auditors of record, Moore & Associates, for professional services rendered
      for the quarterly reviews of our financial statements during 2007 and for the
      audit of our annual financial statements included in our report on Form 10-KSB
      for the year ended December 31, 2007 were approximately $6,000.00.





**Audit
      Related Fees**





For
      the
      fiscal years ended December 31, 2007 and 2006, there were no fees billed for
      assurance and related services by Moore & Associates relating to the
      performance of the audit of our financial statements which are not reported
      under the caption "Audit Fees" above.





**Tax
      Fees**





For
      the
      fiscal years ended December 31, 2007 and 2006, there were no fees billed by
      Moore & Associates for tax compliance, tax advice and tax
      planning.





We
      do not
      use Moore & Associates for financial information system design and
      implementation. These services, which include designing or implementing a system
      that aggregates source data underlying the financial statements or generates
      information that is significant to our financial statements, are provided
      internally or by other service providers. We do not engage Moore &
Associates to provide compliance outsourcing services.





The
      board
      of directors has considered the nature and amount of fees billed by Moore &
Associates and believes that the provision of services for activities unrelated
      to the audit is compatible with maintaining Moore & Associates'
      independence.





41








**SIGNATURES**








In
      accordance with Section 13 or 15(d) of the Exchange Act, the Registrant caused
      this report to be signed on its behalf by the undersigned, thereunto duly
      authorized.






CuraTech
              Industries, Inc.Dated:
              September
              11, 2008
            By:
            /s/
              Lincoln M.
              DastrupLincoln
                M. Dastrup
              Chief
                Executive Officer




In
        accordance with the Exchange Act, this report has been signed below by the
        following persons on behalf of the Registrant and in the capacities and on
        the
        dates indicated.


Signature
            
            Title
            
            Date/s/
              Lincoln M. Dastrup
            
            President,
              Chief
            
            September
              11, 2008Lincoln M. Dastrup
            
            Executive Officer andChief Financial Officer/s/
              Jarom L. Dastrup
            
            Director
              and Executive
            
            September
              11, 2008Jarom L. Dastrup
            
            Vice President/s/
              Linda L. Dastrup
            
            Director
              and Treasurer
            
            September
              11, 2008Linda L. Dastrup




42